<SEC-DOCUMENT>0001193125-25-281498.txt : 20251114
<SEC-HEADER>0001193125-25-281498.hdr.sgml : 20251114
<ACCEPTANCE-DATETIME>20251114070012
ACCESSION NUMBER:		0001193125-25-281498
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251113
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251114
DATE AS OF CHANGE:		20251114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jade Biosciences, Inc.
		CENTRAL INDEX KEY:			0001798749
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				831377888
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40544
		FILM NUMBER:		251481093

	BUSINESS ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		(781) 312-3013

	MAIL ADDRESS:	
		STREET 1:		221 CRESCENT ST.
		STREET 2:		BUILDING 23, SUITE 105
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Aerovate Therapeutics, Inc.
		DATE OF NAME CHANGE:	20200103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d26766d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jbio="http://aerovatetx.com/20251113" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2025-11-13_to_2025-11-13">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-319">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-11-13_to_2025-11-13">0001798749</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="jbio-20251113.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-11-13_to_2025-11-13"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001798749</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-13</xbrli:startDate> <xbrli:endDate>2025-11-13</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-330">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-11-13_to_2025-11-13" format="ixt:datemonthdayyearen" id="ixv-331">November&#160;13, 2025</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-332">Jade Biosciences, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as specified in its charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-11-13_to_2025-11-13" format="ixt-sec:stateprovnameen" id="ixv-333">Nevada</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-334">001-40544</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-335">83-1377888</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:33%"/>
<td style="vertical-align:bottom"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-336">221 Crescent St.</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-337">Building 23</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-338">Suite 105</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center" colspan="3"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-339">Waltham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-340">MA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-341">02453</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center" colspan="3"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-342">(781)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-343">312-3013</ix:nonNumeric></span></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-11-13_to_2025-11-13" format="ixt-sec:boolballotbox" id="ixv-344">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-11-13_to_2025-11-13" format="ixt-sec:boolballotbox" id="ixv-345">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-11-13_to_2025-11-13" format="ixt-sec:boolballotbox" id="ixv-346">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-11-13_to_2025-11-13" format="ixt-sec:boolballotbox" id="ixv-347">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title&#160;of&#160;each&#160;class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name&#160;of&#160;each&#160;exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on&#160;which&#160;registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-348">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-349">JBIO</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-11-13_to_2025-11-13" format="ixt-sec:boolballotbox" id="ixv-350">&#9746;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2025-11-13_to_2025-11-13" format="ixt-sec:boolballotbox" id="ixv-351">&#9746;</ix:nonNumeric></p> <p style="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;2.02.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;13, 2025, Jade Biosciences, Inc. (the &#8220;Company&#8221;) issued a press release announcing the Company&#8217;s financial results for the quarter ended September&#160;30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> (this &#8220;Report&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Item 2.02 and Exhibit 99.1 to this Report are being furnished to the SEC and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, on April&#160;28, 2025 (the &#8220;Closing Date&#8221;), the Company consummated the previously announced business combination pursuant to that certain Agreement and Plan of Merger, dated as of October&#160;30, 2024 (the &#8220;Merger Agreement&#8221;), by and among the Company (f/k/a Aerovate Therapeutics, Inc., a Delaware corporation (&#8220;Aerovate&#8221;)), Caribbean Merger Sub I, Inc., a Delaware corporation and wholly owned subsidiary of Aerovate (&#8220;First Merger Sub&#8221;), Caribbean Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Aerovate (&#8220;Second Merger Sub&#8221;), and Jade Biosciences, Inc., a private Delaware corporation <span style="white-space:nowrap">(&#8220;Pre-Merger</span> Jade&#8221;), pursuant to which, among other matters, <span style="white-space:nowrap">Pre-Merger</span> Jade merged with and into First Merger Sub, with <span style="white-space:nowrap">Pre-Merger</span> Jade continuing as a wholly owned subsidiary of Aerovate and the surviving corporation of the merger (&#8220;First Merger&#8221;) and following the First Merger, <span style="white-space:nowrap">Pre-Merger</span> Jade then merged with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the second merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). Following the Merger, Second Merger Sub merged with and into Aerovate, and Aerovate changed its name to &#8220;Jade Biosciences, Inc.&#8221; Immediately prior to the consummation of the Merger, Aerovate effected a <span style="white-space:nowrap"><span style="white-space:nowrap">1-for-35</span></span> reverse stock split of the common stock, par value $0.0001 per share, of Aerovate (&#8220;Company Common Stock&#8221;), which became effective on April&#160;28, 2025. At the Closing, among other things, the shares of <span style="white-space:nowrap">Pre-Merger</span> Jade common stock and <span style="white-space:nowrap">Pre-Merger</span> Jade <span style="white-space:nowrap">pre-funded</span> warrants were converted into shares of Company Common Stock and <span style="white-space:nowrap">pre-funded</span> warrants to purchase shares of Company Common Stock equal to the exchange ratio of 0.6311 shares of Company Common Stock for each share of <span style="white-space:nowrap">Pre-Merger</span> Jade common stock (the &#8220;Exchange Ratio&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To reflect the Exchange Ratio, the audited financial statements of <span style="white-space:nowrap">Pre-Merger</span> Jade as of December&#160;31, 2024 and June&#160;18, 2024 and for the period from June&#160;18, 2024 (inception) to December&#160;31, 2024 and the related notes thereto have been retroactively adjusted and are filed herewith as Exhibit 99.2. There have been no other changes to such financial statements. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXHIBIT INDEX </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d26766dex231.htm">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d26766dex991.htm">Press release issued on November&#160;13, 2025.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d26766dex992.htm">Audited Financial Statements of Jade Biosciences, Inc. as of December&#160;31, 2024 and June&#160;18, 2024 and for the period from June&#160;18, 2024 to December&#160;31, 2024.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover page interactive data file (embedded within the inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Jade&#160;Biosciences,&#160;Inc.</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" colspan="3">(Registrant)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: November&#160;14, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tom Frohlich</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Tom Frohlich</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d26766dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 23.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the incorporation by reference in the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> (No. <FONT
STYLE="white-space:nowrap">333-288425)</FONT> of Jade Biosciences, Inc. of our report dated February&nbsp;24, 2025, except for the effects of the reverse merger exchange ratio discussed in Note 1 to the financial statements, as to which the date is
November&nbsp;14, 2025, relating to the financial statements which appears in this Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
PricewaterhouseCoopers LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;14, 2025 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d26766dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated
biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> selective anti-APRIL monoclonal antibody for IgA
nephropathy </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Initiated Phase 1 healthy volunteer study of JADE101; interim, biomarker-rich data expected in the first half
of 2026 are anticipated to define dose and dose interval selection for patient trials</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Unveiled JADE201, a potentially
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class,</FONT></FONT> half-life extended, afucosylated anti-BAFF receptor monoclonal antibody;
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial in rheumatoid arthritis expected to begin in the first half of 2026 with potential opportunity across multiple autoimmune diseases validated by <FONT
STYLE="white-space:nowrap">BAFF-R</FONT> biology</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Completed $135</I><I></I><I>&nbsp;million private placement, extending cash runway into the first half of 2028
</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>San Francisco and Vancouver, British Columbia &#8211; </B>November&nbsp;13, 2025 &#8211; Jade Biosciences, Inc.
(&#8220;Jade&#8221;) (Nasdaq: JBIO), a biotechnology company focused on developing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapies for autoimmune diseases, today announced financial results for
the quarter ending September&nbsp;30, 2025, and provided a corporate update. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;The third quarter marked meaningful progress toward our mission of
delivering potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapies for autoimmune diseases,&#8221; said Tom Frohlich, Chief Executive Officer of Jade Biosciences. &#8220;At the recent ASN
Kidney Week, we presented preclinical safety and translational data that support JADE101&#8217;s potential to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class,</FONT></FONT> selective anti-APRIL therapy and
provide further confidence that biomarker data from our ongoing Phase 1 healthy volunteer trial will define the dosing strategy for IgAN patient studies. We also introduced our second development candidate, JADE201, which builds on validated <FONT
STYLE="white-space:nowrap">BAFF-R</FONT> biology to potentially address a broad range of autoimmune diseases, and completed a $135&nbsp;million private financing. With these achievements, we are well positioned to execute on multiple clinical
milestones and bring further innovation in autoimmune disease treatment.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pipeline and Corporate Updates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>JADE101: potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> selective anti-APRIL monoclonal
antibody for IgA nephropathy (IgAN) </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Presented two posters at the American Society of Nephrology (ASN) Kidney Week 2025. JADE101 is an ultra-high
affinity, half-life-extended fully human monoclonal antibody that has the potential for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> activity with convenient patient dosing. JADE101 is an ultra-high
affinity, half-life-extended fully human monoclonal antibody that has the potential for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> activity with convenient patient dosing. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a poster presentation of <FONT STYLE="white-space:nowrap">non-clinical</FONT> safety data, JADE101 was well
tolerated in NHPs at all doses tested preclinically, including at the highest dose establishing the no-observed-adverse-effect level (NOAEL), supporting the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> doses being evaluated in the ongoing Phase 1 trial. JADE101 showed no <FONT STYLE="white-space:nowrap">off-target</FONT> binding, tissue cross-reactivity,
or cytokine release and produced reversible, mechanism-consistent reductions in serum immunoglobulins (IgA, IgM, IgG) without evidence of broad immune suppression, reinforcing its potential as a well-tolerated and selective
therapy.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A second poster presentation described a translational assessment demonstrating consistency of biomarker
responses to APRIL inhibition across NHPs, healthy volunteers and IgAN patients, showing that pharmacokinetic and biomarker responses observed in healthy volunteers are predictive of anticipated therapeutic outcomes in IgAN patients. These analyses
link the depth and duration of APRIL suppression to expected reductions in IgA, <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> and proteinuria associated with kidney function preservation, supporting that biomarker data from the ongoing Phase 1
study will define dose and dosing interval selection for IgAN patient trials and enable convenient, infrequent subcutaneous dosing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Initiated enrollment in Phase 1 clinical trial evaluating JADE101 administered as a subcutaneous injection in
healthy volunteers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Interim, biomarker-rich data are expected in the first half of 2026 and are anticipated to define the dose and
dose interval for Phase 2 and Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>JADE201: potentially <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">anti-BAFF-R</FONT> monoclonal antibody for autoimmune diseases </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Introduced JADE201, a half-life extended, afucosylated monoclonal antibody targeting the <FONT
STYLE="white-space:nowrap">B-cell</FONT> activating factor receptor <FONT STYLE="white-space:nowrap">(BAFF-R).</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">JADE201 is designed to overcome the limitations of current B cell-directed therapies by combining a dual
mechanism of action and half-life extension technology, with the goal of improving on the clinical benefit of existing <FONT STYLE="white-space:nowrap">B-cell</FONT> depleting therapies across a broad range of autoimmune diseases with less frequent
subcutaneous dosing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">JADE201 builds on the clinical
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for <FONT STYLE="white-space:nowrap">BAFF-R</FONT> targeting established by ianalumab, which met primary endpoints in recent Phase 3 Sjogren&#8217;s and
idiopathic thrombocytopenic purpura trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In NHP studies, JADE201 showed high-affinity <FONT STYLE="white-space:nowrap">BAFF-R</FONT> binding, achieved
dose-dependent BAFF receptor occupancy, sustained <FONT STYLE="white-space:nowrap">B-cell</FONT> depletion, and demonstrated an approximately <FONT STYLE="white-space:nowrap">two-fold</FONT> extended half-life versus ianalumab.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial evaluating
JADE201 in rheumatoid arthritis is expected to begin in the first half of 2026, with potential for broad opportunity across multiple autoimmune diseases validated by <FONT STYLE="white-space:nowrap">BAFF-R</FONT> biology. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completed a $135&nbsp;million private placement with participation from new and existing leading healthcare
investors. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third Quarter 2025 Financial Results </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cash Position:</B> As of September&nbsp;30, 2025, Jade had cash, cash equivalents, and investments of
$198.9&nbsp;million. In October, the Company closed on a $135&nbsp;million private placement financing, resulting in cash, cash equivalents, and investments of approximately $325.6&nbsp;million on a <FONT STYLE="white-space:nowrap">pro-forma</FONT>
basis as of September&nbsp;30, 2025. Based on its current operating plans, Jade believes that its existing cash will enable it to fund its operating expenses and capital expenditure requirements into the first half of 2028. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Research and Development (R&amp;D) expenses: </B>R&amp;D expenses totaled $22.0&nbsp;million for the third
quarter ended September&nbsp;30, 2025, compared to $13.6&nbsp;million for the quarter ended September&nbsp;30, 2024. R&amp;D expenses increased primarily due to higher personnel-related costs as the Company builds out the internal R&amp;D function
as well as increased costs around CMC and early clinical activity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>General and Administrative (G&amp;A) expenses:</B> G&amp;A expenses totaled $5.4&nbsp;million for the third
quarter ended September&nbsp;30, 2025, compared to $1.4&nbsp;million for the quarter ended September&nbsp;30, 2024. G&amp;A expenses increased primarily due to higher personnel-related costs as the Company builds out its internal infrastructure.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Net loss:</B> Net loss totaled $25.2&nbsp;million for the third quarter ended September&nbsp;30, 2025,
compared to a net loss of $16.3&nbsp;million for the quarter ended September&nbsp;30, 2024. Net loss increased primarily as a result of higher R&amp;D and G&amp;A expenses, as described above. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Shares Outstanding: </B>After giving effect to the Company&#8217;s recently completed $135&nbsp;million
private placement, Jade had 67,394,380&nbsp;million shares of the Company&#8217;s common stock and common stock equivalents issued and outstanding, including shares of common stock underlying <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants and <FONT STYLE="white-space:nowrap">non-voting</FONT> convertible preferred. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Jade Biosciences, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jade Biosciences is a clinical-stage biotechnology company focused on developing
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapies that address critical unmet needs in autoimmune diseases. Jade&#8217;s lead candidate, JADE101, targets the cytokine APRIL, and is currently
being evaluated in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. Jade&#8217;s pipeline also includes JADE201, an afucosylated <FONT STYLE="white-space:nowrap">anti-BAFF-R</FONT> monoclonal antibody, as well as <FONT
STYLE="white-space:nowrap">JADE-003,</FONT> an undisclosed antibody discovery program, both currently in preclinical development.&nbsp;Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by
Fairmount. For more information, visit&nbsp;JadeBiosciences.com&nbsp;and follow the Company on&nbsp;LinkedIn.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain statements in this communication, other than purely historical information, may constitute &#8220;forward-looking statements&#8221; within the meaning
of the federal securities laws, including for purposes of the &#8220;safe harbor&#8221; provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied
statements relating to Jade&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade&#8217;s ability to achieve the expected benefits or opportunities with
respect to JADE101, JADE201 and <FONT STYLE="white-space:nowrap">JADE-003,</FONT> the expected timelines for interim data from the Phase 1 clinical trial of JADE101 and for JADE201 entering the clinic, plans for future clinical trials, the potential
of Jade&#8217;s product candidates to become <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> therapies, their potential therapeutic uses, efficacy, safety profiles, and dosing, and the potential for
Jade&#8217;s cash runway to extend into the first half of 2028. The words &#8220;opportunity,&#8221; &#8220;potential,&#8221; &#8220;milestones,&#8221; &#8220;pipeline,&#8221; &#8220;can,&#8221; &#8220;goal,&#8221; &#8220;strategy,&#8221;
&#8220;target,&#8221; &#8220;anticipate,&#8221; &#8220;achieve,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221;
&#8220;may,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions (including the negatives of these terms or variations of them) may identify
forward-looking statements, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments
and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade&#8217;s
control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that
the Phase 1 clinical trial of JADE101, the planned trial of JADE201 and any future clinical trials may be delayed or may not demonstrate desirable efficacy; adverse events and safety signals may occur; Jade may experience unanticipated costs,
difficulties or delays in the product development process; Jade&#8217;s product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; enrollment or
regulatory challenges; risks associated with Jade&#8217;s dependence on third-party vendors for the development, manufacture and supply of its product candidates; and the other risks, uncertainties and factors more fully described in Jade&#8217;s
most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2025). Should one or more of these risks or uncertainties
materialize, or should any of Jade&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this
communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any
forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jade Biosciences Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Priyanka Shah </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media@JadeBiosciences.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR@JadeBiosciences.com </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">908-447-6134</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JADE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">198,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 69,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 72,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 23,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, Series Seed convertible preferred stock and stockholders&#8217; equity
(deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">202,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 72,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JADE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months<BR>Ended<BR>September&nbsp;30,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months<BR>Ended<BR>September&nbsp;30,<BR>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months<BR>Ended<BR>September&nbsp;30,<BR>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period&nbsp;from&nbsp;June&nbsp;18,</B><br><B>2024<BR>(Inception)Through<BR>September&nbsp;30, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 22,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 13,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 64,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 13,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(27,401</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,965</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(78,563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Convertible Notes
payable<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,312</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,277</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16,867</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194; &#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (25,122)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (16,277)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (95,449)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 16,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (0.48)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (5.16)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (3.08)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (5.35)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to Series A <FONT STYLE="white-space:nowrap">non-voting</FONT>
convertible preferred stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (482.25)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (3,081.78)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to common stockholders,
basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,584,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,155,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,816,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,155,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used in computing net loss per share attributable to Series A <FONT
STYLE="white-space:nowrap">non-voting</FONT> convertible preferred stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amounts of $5.8&nbsp;million and $17.5&nbsp;million for the three and nine months ended
September&nbsp;30, 2025, respectively, and $13.1&nbsp;million for the three months ended September&nbsp;30, 2024 and $13.2&nbsp;million for the period from June&nbsp;18, 2024 (inception) through September&nbsp;30, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amounts of $0.2&nbsp;million for both the three and nine months ended September&nbsp;30,
2025, and $0.4&nbsp;million for the three months ended September&nbsp;30, 2024 and $0.9&nbsp;million for the period from June&nbsp;18, 2024 (inception) through September&nbsp;30, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amounts of $4.6&nbsp;million for the nine months ended September&nbsp;30, 2025, and none
for the three months ended September&nbsp;30, 2025. Includes related party amounts of $0.4&nbsp;million for the period from June&nbsp;18, 2024 (inception) through September&nbsp;30, 2024. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>d26766dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin16462_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Board of Directors and Stockholders of Jade Biosciences, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Jade Biosciences, Inc. (the &#8220;Company&#8221;) as of December&nbsp;31, 2024
and June&nbsp;18, 2024, and the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; deficit and cash flows for the period from June&nbsp;18, 2024 (inception) to December&nbsp;31,
2024, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the
Company as of December&nbsp;31, 2024 and June&nbsp;18, 2024, and the results of its operations and its cash flows for the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024 in conformity with accounting principles generally
accepted in the United States of America. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern</I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed
in Note 1 to the consolidated financial statements, the Company has incurred significant operating losses and negative cash flows from operations since inception that raise substantial doubt about its ability to continue as a going concern.
Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These
consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm
registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated financial statements in accordance with
the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to
assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the
amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated
financial statements. We believe that our audits provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ PricewaterhouseCoopers LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February&nbsp;24, 2025 except for the
effects of the reverse merger exchange ratio discussed in Note 1 to the financial statements, as to which the date is November&nbsp;14, 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
served as the Company&#8217;s auditor since 2024. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JADE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin16462_2"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;18,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party subscription receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability, related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized as of
December&nbsp;31, and June&nbsp;18, 2024; 20,000,000 shares issued and outstanding as of December&nbsp;31, 2024 and June&nbsp;18, 2024, respectively; liquidation preference of $2 and $2 as of December&nbsp;31, 2024 and June&nbsp;18, 2024,
respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 40,000,000 shares authorized, 3,672,794 shares issued and
outstanding as of each of December&nbsp;31, 2024 and June&nbsp;18, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amount of $22.7&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JADE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin16462_3"></A>CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share amounts)</I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18, 2024<BR>(Inception) to<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 31,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(35,538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income / (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes
payable<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(12,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,155,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amount of $24.6&nbsp;million for the period from June&nbsp;18, 2024 (inception) to
December&nbsp;31, 2024 (see Note 13). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amount of $1.0&nbsp;million for the period from June&nbsp;18, 2024 (inception) to
December&nbsp;31, 2024 (see Note 13). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amount of $2.7&nbsp;million for the period from June&nbsp;18, 2024 (inception) to
December&nbsp;31, 2024 (see Note 13). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial
statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JADE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin16462_4"></A>CONSOLIDATED STATEMENT OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share amounts) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible</B><br><B>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#8217;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of June&nbsp;18, 2024 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,672,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balances as of December&nbsp;31, 2024</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,672,794</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,799</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JADE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin16462_5"></A>CONSOLIDATED STATEMENT OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18, 2024<BR>(Inception) to<BR>December&nbsp;31,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(46,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of convertible notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,614</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible notes
payable<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of <FONT STYLE="white-space:nowrap">non-cash</FONT> financing
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs in accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes related party amount of $20.0&nbsp;million for the period from June&nbsp;18, 2024 (inception) to
December&nbsp;31, 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>JADE BIOSCIENCES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin16462_6"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Nature of the Business and Basis of Presentation</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background and Basis of Presentation</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jade Biosciences, Inc. (&#8220;Jade&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of
Delaware on June&nbsp;18, 2024. Jade was founded by healthcare investor Fairmount Funds Management LLC (&#8220;Fairmount&#8221;) and launched to research and develop antibody candidates licensed from Paragon Therapeutics, Inc.
(&#8220;Paragon&#8221;), an antibody discovery engine founded by Fairmount. The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Jade was formed to develop
biologics to optimize the treatment of autoimmune diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to risks and uncertainties common to early-stage
companies in the biopharmaceutical industry, including, but not limited to, the ability to complete preclinical and clinical trials, the ability to obtain regulatory approval for product candidates, development by competitors of new technological
innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of
market acceptance of products and the ability to raise additional capital to fund operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s potential product
candidates will require approval from the U.S. Federal Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential product candidates will
receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential product candidates, if approved, will be accepted in the marketplace, that any future product candidates can be developed or manufactured
at an acceptable cost and with appropriate performance characteristics, or that such product candidates will be successfully marketed, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Aerovate Therapeutics, Inc., a Delaware corporation (&#8220;Aerovate&#8221;), and the Company entered into an Agreement and Plan of Merger
(the &#8220;Merger Agreement&#8221;) on October&nbsp;30, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Caribbean Merger Sub I, Inc., a Delaware
corporation, will merge with and into Jade, with Jade continuing as a wholly owned subsidiary of Aerovate and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Jade will merge with and into Caribbean Merger Sub II, LLC, a
Delaware limited liability company (&#8220;Second Merger Sub&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with
the Merger, Second Merger Sub will change its corporate name to &#8220;Jade Biosciences, LLC&#8221; and Aerovate will change its name to &#8220;Jade Biosciences, Inc.&#8221; Aerovate following the Merger is referred to herein as the &#8220;combined
company.&#8221; The combined company will be led by Jade&#8217;s management team and will focus on developing differentiated biologic therapies for patients living with autoimmune diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), (i) each share of Jade common stock (including shares of
Jade common stock issued in the Jade <FONT STYLE="white-space:nowrap">pre-closing</FONT> financing described below) will be converted into the right to receive a number of shares of Aerovate common stock equal to the exchange ratio set forth in the
Merger Agreement (the &#8220;Exchange Ratio&#8221;) and (ii)&nbsp;each share of Jade Series Seed Convertible Preferred Stock, par value $0.0001 per share (the &#8220;Convertible Preferred Stock&#8221;), will be converted into the right to receive a
number of shares of Aerovate Series A <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock equal to the exchange ratio divided by 1,000. If any shares of Jade common stock are unvested or subject to a repurchase option or
risk of forfeiture at the First Effective Time (the &#8220;Jade restricted common stock&#8221;), then the shares of Aerovate common stock issued in exchange for such shares will to the same extent be unvested and subject to the same repurchase
option or risk of forfeiture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;30, 2024, concurrent with the execution of the Merger Agreement, the Company
entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with certain investors pursuant to which the Company agreed to issue and sell to such investors in a private placement financing (the &#8220;Private Placement&#8221;)
shares of the Company&#8217;s common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of the Company&#8217;s common stock at an estimated purchase price of $5.9407 per share of common stock and $5.9406 per <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant (before giving effect to the Exchange Ratio), for gross proceeds of approximately $300.0&nbsp;million (which includes $95.0&nbsp;million of proceeds previously received from the issuance of
convertible notes (the &#8220;Convertible Notes&#8221;)), which will precede the closing of the Merger. Shares of the Company&#8217;s common stock issued pursuant to the Private Placement will be converted into shares of Aerovate common stock in
accordance with the exchange ratio at the effective time of the close of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements and
accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;28, 2025 (the &#8220;Closing Date&#8221;), the Company consummated the previously announced transaction pursuant to the Merger
Agreement. The Exchange Ratio was calculated as 0.6311 shares of Aerovate common stock for each share of Jade common stock (and 0.0006311 shares of Series A Preferred Stock for each share of Jade Series Seed Convertible Preferred Stock) on the
Closing Date, which gives effect to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-35</FONT></FONT> reverse stock split of shares of Aerovate common stock immediately prior to the Merger. The par value per share and the
number of authorized shares were not adjusted as a result of the Exchange Ratio. The shares of Company common stock underlying outstanding stock options, restricted stock awards, and other equity instruments were proportionately reduced and the
respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All references to common stock, options to purchase common stock, common stock share data, per share
data, and related information contained in the consolidated financial statements have been retrospectively adjusted to reflect the effect of the Exchange Ratio for all periods presented, unless otherwise specifically indicated or the context
otherwise requires. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the
Company&#8217;s ability to continue as a going concern within twelve months of the date that the consolidated financial statements are issued. As of December&nbsp;31, 2024, the Company had $69.4&nbsp;million in cash and cash equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will devote substantially all of its resources to advancing the development of its programs, organizing and staffing the Company
business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the
Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its potential product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its
internal commercialization capability to support product sales, marketing, and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the Company will need
substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its potential product candidates are approved, proceeds
to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate
funding may not be available to the Company on acceptable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company is unable to obtain additional funding, the
Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern. The consolidated financial statements do not
include any adjustments that may result if the Company is not able to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has not generated any
revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred a net loss of $47.0&nbsp;million during the period from June&nbsp;18, 2024
(inception) to December&nbsp;31, 2024. As of December&nbsp;31, 2024, the Company had an accumulated deficit of $47.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
July 2024, the Company received $80.0&nbsp;million in gross proceeds from the issuance of Convertible Notes under the Purchase Agreement to several investors, of which Fairmount, through an affiliate fund, holds a Convertible Note with an initial
principal amount of $20.0&nbsp;million, which qualifies as a related party transaction (see Note 13). In September 2024, the Company received an additional $15.0&nbsp;million in gross proceeds from issuing Convertible Notes to additional investors
under the Purchase Agreement (see Note 5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution of the Merger Agreement, certain parties have entered into the
Subscription Agreement with Jade to purchase, prior to the consummation of the Merger, shares of Jade common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants at an estimated purchase price of $5.9407 and $5.9406 per share
(before giving effect to the Exchange Ratio), respectively, for aggregate gross cash proceeds of approximately $300.0&nbsp;million, which includes the $95.0&nbsp;million of Jade Convertible Notes previously issued. Shares of Jade common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of Jade common stock issued pursuant to the Subscription Agreement will be converted into shares of Aerovate common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants to purchase shares of Aerovate common stock at the closing of the Merger per the Merger Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, the completion of
the transactions is subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at
all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on its expectations of continuing operating losses and negative cash flows from operations for the foreseeable future, as of
February&nbsp;24, 2025, the date the Company&#8217;s consolidated financial statements are available to be issued, the Company has concluded that there is substantial doubt about its ability to continue as a going concern for at least 12 months from
the date the consolidated financial statements are available to be issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements do not
include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the consolidated financial
statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
November 2024, the Company formed Jade Biosciences Canada ULC and Jade Biosciences Security Corporation, both of which are wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation
of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets and liabilities and the disclosure of contingent
assets and liabilities at the date of the consolidated financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected within these consolidated financial statements include but are not limited to
research and development expenses and related prepaid or accrued costs, the valuation of stock-based compensation awards and related expenses, and the valuation of outstanding convertible notes. The Company bases its estimates on known trends and
other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results may
differ materially from those estimates or assumptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions. The
Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s financial information for purposes of evaluating financial performance and allocating resources (see Note 14).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentrations of Credit Risk</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash. The Company maintains its
cash balances at accredited financial institutions in amounts that, at times, may exceed federally insured limits. However, the Company has not experienced any losses on its deposits of cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is dependent on third-party organizations to research, develop, manufacture, and process its potential product candidates for its
development programs. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could be adversely affected by a
significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s research and development activities are performed under its agreements with Paragon (see Note 10). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of initial purchase to be cash equivalents. The cash equivalents were comprised of an investment in a money market fund. Interest
income associated with the cash equivalents will be recorded as other income in the consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company capitalizes certain legal, professional, accounting, and other third-party fees that are directly associated with <FONT STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such financings are
consummated. After the consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders&#8217; deficit as a
reduction of additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to
operating expenses in the consolidated statement of operations and comprehensive loss. As of December&nbsp;31, 2024, deferred offering costs of $3.1&nbsp;million were recorded as Other assets in the consolidated balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subscription receivable</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company accounts for any notes received in exchange for common stock, including those with related parties as a subscription receivable, provided the note underlying the receivable is paid prior to the date the consolidated financial statements are
available to be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value Measurements</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain assets and liabilities are carried at fair value under U.S. GAAP. Fair value is defined as the exchange price that would be received
for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure
fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value
hierarchy, of which the first two are considered observable and the last is considered unobservable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1&#8201;-&#8201;Quoted prices in active markets that are identical assets or liabilities.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2&#8201;-&#8201;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in
active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3&#8201;-&#8201;Unobservable inputs that are supported by little or no market activity that are
significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note 3).
The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity periods. The Company has
elected the fair value option (&#8220;FVO&#8221;) for its Convertible Notes. The analysis of the fair value of the Convertible Notes contains inherent assumptions related to the market interest rate, instrument-specific credit risk, the probability
of alternate financing, change of control, initial public offering, maturity extension, and payment at original maturity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the use
of significant unobservable inputs, the overall fair value measurement of the Convertible Notes is classified as Level&nbsp;3. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classification of
Convertible Preferred Stock</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has classified the Convertible Preferred Stock outside of stockholders&#8217; equity on the
Company&#8217;s consolidated balance sheets because the holders of such stock have certain liquidation rights in the event of a Deemed Liquidation Event that, in certain situations, is not solely within the control of the Company and would require
the redemption of the then-outstanding Convertible Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible Preferred Stock is not redeemable, except in the
event of deemed liquidation (see Note 6). Because the occurrence of a Deemed Liquidation Event is not currently probable, the carrying values of the Convertible Preferred Stock are not being accreted to their redemption values. Subsequent
adjustments to the carrying values of the Convertible Preferred Stock would be made only when a Deemed Liquidation Event becomes probable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Convertible Notes Payable</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company performed an analysis of all of the terms and features of the Convertible Notes and has elected the FVO to account for the Convertible Notes to address simplification as the Company has identified embedded derivatives, such as automatic
conversion upon the closing of a $25.0&nbsp;million or greater financing event, including an initial public offering (a &#8220;Next Equity Financing&#8221;), and automatic conversion upon certain events (e.g., a sale of substantially all Company
assets, a merger, etc.), both of which would require bifurcation and separate accounting. The Convertible Notes will be remeasured at fair value at each balance sheet date until repayment or conversion. Changes to the fair value of the Convertible
Notes will be recorded in other income (expense), net in the Company&#8217;s consolidated statement of operations and comprehensive loss. The Company has also elected the option of combining interest expense and the change in fair value as a single
line item within the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#8217;s consolidated statement of operations and comprehensive loss. Changes in fair value resulting from changes in instrument-specific credit risk, if any, will be recognized separately
in other comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Contract Costs Accruals</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant
component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third-party service providers, including contract research organizations
(&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related party Paragon (see Note 10). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accrues for expenses resulting from obligations under its antibody discovery and option agreement (as amended, the &#8220;Paragon
Option Agreement&#8221;) by and among the Company, Paragon and Parade Biosciences Holding LLC (&#8220;Parade&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and agreements with CROs, CMOs, and other outside service
providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with
Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as
to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside
service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect
the Company&#8217;s results of operations. As of December&nbsp;31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred. Research and development costs include amounts reimbursed to Paragon under the Paragon
Option Agreement (see Note 10), salaries and bonuses, stock-based compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded
as prepaid expenses on the accompanying consolidated balance sheets. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the
services rendered. If nonrefundable advance payments represent a <FONT STYLE="white-space:nowrap">one-time</FONT> cost for obtaining goods or services, with anticipated benefits to be utilized within a year of
<FONT STYLE="white-space:nowrap">period-end,</FONT> the payment is expensed immediately. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries and bonuses, stock-based compensation, employee benefits, finance and
administration costs, and professional fees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Commitments and Contingencies</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may be subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business
activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range
is recorded as a liability on the consolidated balance sheets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses.
As of December&nbsp;31, 2024, no liabilities were recorded for loss contingencies (see Note 11). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company classifies stock-based compensation expense in its consolidated statement of operations and comprehensive loss in the same manner
in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company grants stock options and restricted stock awards that are subject to service-based vesting conditions. Compensation expense for
awards to employees and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to
<FONT STYLE="white-space:nowrap">non-employees</FONT> with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the
award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the
performance-based vesting condition will be achieved. The Company has issued stock options and restricted common stock awards (&#8220;RSAs&#8221;) with service-based vesting conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures all stock-based awards granted to employees, directors, and <FONT STYLE="white-space:nowrap">non-employees</FONT> in the
form of stock options to purchase shares of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. The Company measures RSAs using the difference, if any, between the purchase price
per share of the award and the fair value of the Company&#8217;s common stock at the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s common stock
valuations were prepared using a hybrid method, including an option pricing method (&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value
thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock
liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is
calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based on the
probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to
the valuation date at an appropriate risk- adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication
of value for the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved
inherent uncertainties and the application of management&#8217;s judgment. As a result, if the Company had used significantly different assumptions or estimates, the fair value of incentive shares and stock-based compensation expense could have been
materially different. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share Attributable to Common Stockholders</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company applies the <FONT STYLE="white-space:nowrap">two-class</FONT> method when computing net loss per share attributable to the
Company&#8217;s common stockholders as the Company has issued shares that meet the definition of participating securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net loss per share for each class of common and
participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">two-class</FONT> method requires loss available to common stockholders for the period to be allocated between common and participating securities based upon their
respective rights to share in the undistributed earnings as if all loss for the period had been distributed. The Company considers its Convertible Preferred Stock to be participating securities as, in the event a dividend is paid on common stock,
the holders of Convertible Preferred Stock would be entitled to receive dividends on a basis consistent with the Company&#8217;s common stockholders. There is no allocation required under the <FONT STYLE="white-space:nowrap">two-class</FONT> method
during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to the Company&#8217;s common
stockholders by the weighted average number of common shares outstanding for the period, excluding potentially dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable to
common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss by the weighted average number
of common shares outstanding for the period, including potentially dilutive securities. For purposes of this calculation, the Company&#8217;s outstanding Convertible Preferred Stock, stock options to purchase common stock and unvested RSAs are
considered potentially dilutive common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company generated a net loss for the period presented. In periods in which the Company
reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have
been issued if their effect is anti-dilutive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and
liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the differences
between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the
provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not
that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertainty in income taxes
recognized in the consolidated financial statements by applying a <FONT STYLE="white-space:nowrap">two-step</FONT> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated
financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax
reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of both June&nbsp;18, 2024
and December&nbsp;31, 2024. The Company did not have any uncertain tax positions as of both June&nbsp;18, 2024 and December&nbsp;31, 2024. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) <FONT
STYLE="white-space:nowrap">No.&nbsp;2023-07,</FONT> <I>Segment Reporting</I> (<I>Topic 280</I>) (&#8220;ASU <FONT STYLE="white-space:nowrap">2023-07&#8221;),</FONT> which enhances the segment disclosure requirements for public entities on an annual
and interim basis. Under this proposal, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current
annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at the Company along with an
explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> requires all segment
disclosures for public entities that have only a single reportable segment. The amendments in ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> are effective for fiscal years beginning after December&nbsp;15, 2023, and interim periods within
fiscal years beginning after December&nbsp;15, 2024. Early adoption is permitted. The Company adopted and applied the new disclosure requirements in these consolidated financial statements (see Note 14). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued ASU <FONT STYLE="white-space:nowrap">2023-09,</FONT> <I>Income Taxes (Topic 740): Improvements to Income Tax
Disclosures</I>. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S. and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025
fiscal year annual reporting period. The Company is currently evaluating the impact of this standard on its consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <FONT STYLE="white-space:nowrap">2024-03,</FONT> <I>Income Statement-Reporting Comprehensive
Income-Expense Disaggregation Disclosures (Subtopic <FONT STYLE="white-space:nowrap">220-40):</FONT> Disaggregation of Income Statement Expenses </I>(&#8220;ASU <FONT STYLE="white-space:nowrap">2024-03&#8221;).</FONT> The amendments in ASU <FONT
STYLE="white-space:nowrap">2024-03</FONT> require public entities to disclose specified information about certain costs and expenses. ASU <FONT STYLE="white-space:nowrap">2024-03</FONT> is effective for the Company&#8217;s annual reporting period
beginning after December&nbsp;15, 2026 and interim reporting periods beginning after December&nbsp;27, 2027, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Fair Value Measurements</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December&nbsp;31, 2024 and indicates the fair value hierarchy of the valuation inputs the Company
utilized to determine the fair value (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash equivalents consist of money market funds, which were valued by the Company based on quoted market
prices, which represent a Level&nbsp;1 measurement within the fair value hierarchy. The Convertible notes payable are revalued at each remeasurement date using inputs that are generally unobservable and reflect management&#8217;s estimates of
assumptions that market participants would use in pricing the liability, which </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
represent a Level&nbsp;3 measurement within the fair value hierarchy. For the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024, there were no transfers between Level&nbsp;1,
Level&nbsp;2 and Level&nbsp;3. There were no financial assets and liabilities that were measured on fair value at a recurring basis as of June&nbsp;18, 2024 (inception). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the changes in the fair value of the Level&nbsp;3 Convertible notes payable (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amounts</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of June&nbsp;18, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of Convertible notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible notes payable in the table above consists of the fair value of an aggregate principal amount
of $95.0&nbsp;million, and a fair value adjustment of $12.6&nbsp;million, which includes accrued interest of $4.7&nbsp;million, in Convertible Notes which the Company issued and sold to certain investors. Each holder of Convertible Notes is expected
to contribute the principal amount and all accrued interest under the applicable Convertible Note in exchange for the Company&#8217;s common stock or <FONT STYLE="white-space:nowrap">non-voting</FONT> preferred stock in connection with a financing
event under the Convertible Notes (see Note 5). The Company&#8217;s valuation of the Convertible Notes payable utilizes a scenario-based valuation analysis, which incorporated assumptions and estimates to value the Convertible Notes and a
probability assessment of the achievement of the Next Equity Financing. The Company assesses these assumptions and estimates on a quarterly basis as additional information impacting the assumptions is obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible Notes were issued on July&nbsp;24, 2024 and September&nbsp;30, 2024. The following table presents the significant assumptions
related to the change in fair value for the period ending December&nbsp;31, 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time from convertible notes issuance to Next Equity Financing (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">0.58&#8201;-&#8201;0.77</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of Next Equity Financing</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time from convertible notes issuance to Next Equity Financing / prior to trade sale (in
years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.75&#8201;-&#8201;0.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Probability of Next Equity Financing / prior to trade sale</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Accrued Expenses and Other Current Liabilities</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development contract costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee compensation and benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional and consulting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Convertible Notes Payable</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2024, the Company entered into a Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with a series of investors,
pursuant to which the Company issued Convertible Notes with an initial principal amount of $80.0&nbsp;million (of which $20.0&nbsp;million is from a related party). In September 2024, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company received an additional $15.0&nbsp;million in gross proceeds from issuing additional Convertible Notes to additional investors. The principal amount and all accrued interest of the
Convertible Notes will automatically convert into the Company&#8217;s common stock or preferred stock in connection with the closing of a Next Equity Financing or other events (e.g., a sale of substantially all Company assets, a merger, etc.). The
Convertible Notes accrue interest at a rate of 12.0% per annum, compounded annually. All unpaid interest and principal are scheduled to mature on December&nbsp;31, 2026 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without prior
written consent of the majority of the holders of the Convertible Notes. The principal payment along with the accrued interest on each Convertible Note is due in full on the Maturity Date. As of December&nbsp;31, 2024, the Company had outstanding
borrowings of $95.0&nbsp;million under its Convertible Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the automatic conversions described above, the
Convertible Notes will convert into a number of shares of common stock equal to the quotient obtained by dividing the initial purchase price plus accrued and unpaid interest by the conversion price of the Convertible Notes, which is the product
resulting from multiplying the price per share in the Next Equity Financing by 80%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible Notes were recorded at the fair value
of $95.0&nbsp;million on the respective issuance dates and were remeasured to the fair value of $107.6&nbsp;million as of December&nbsp;31, 2024. The change in the fair value of the Convertible Notes of $12.6&nbsp;million, which includes accrued
interest of $4.7&nbsp;million, was recorded within other expense, net on the Company&#8217;s consolidated statement of operations and comprehensive loss for the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. There was less
than $0.1&nbsp;million of debt issuance cost incurred in connection with the Convertible Notes. This amount was recognized as general and administrative expense in the Company&#8217;s consolidated statement of operations and comprehensive loss
during the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Convertible Preferred Stock</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2024, the Company issued 20,000,000 shares of the Convertible Preferred Stock to a related party, Fairmount Healthcare Fund II
L.P., an affiliate fund of Fairmount, at a purchase price of $0.0001 per share for gross proceeds of less than $0.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
the issuance of the Convertible Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these
features as embedded derivatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024 and June&nbsp;18, 2024, Convertible Preferred Stock consisted of the
following (in thousands, except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2024 and June&nbsp;18, 2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock<BR>Issued&nbsp;and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock<BR>Issuable Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series Seed Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,622,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,622,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Convertible Preferred Stock have the following rights and preferences: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Convertible
Preferred Stock are entitled to vote, together with the holders of the Company&#8217;s common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Convertible Preferred Stock is entitled to the number of
votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholders entitled to vote on such matter. A majority vote of the holders of Convertible Preferred Stock is required to liquidate or dissolve the Company, amend the certificate of
incorporation or bylaws in a manner that adversely affects the rights of the Convertible Preferred Stock, reclassify common stock or establish another class of capital stock (unless the same ranks junior to the Convertible Preferred Stock with
respect to its rights), create shares that would rank senior to or authorize additional shares of Convertible Preferred Stock, declare a dividend or make a distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the holders of shares of Convertible Preferred Stock are entitled to elect one director of the Company. The holders of shares of
common stock and any other class or series of voting stock (including Convertible Preferred Stock), exclusively and voting together as a single class, are entitled to elect the balance of the total number of directors of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of
Convertible Preferred Stock is convertible into common shares at the option of the holder, at any time, and without the payment of additional consideration by the holder. Additionally, in the event of a mandatory conversion, such as the Merger, each
share of Convertible Preferred Stock will be automatically converted into shares of newly created <FONT STYLE="white-space:nowrap">non-voting</FONT> preferred stock at the applicable conversion ratio then in effect upon (i)&nbsp;the closing of a
firm-commitment underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0&nbsp;million of gross proceeds to the Company, net of the underwriting discount and commissions, and
(ii)&nbsp;the vote or written consent of the holders of a majority of the outstanding shares of preferred stock, voting as a single class. The rights, privileges, duties and obligations relating to the
<FONT STYLE="white-space:nowrap">non-voting</FONT> preferred stock are to be determined at the time of a mandatory conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
conversion ratio of Convertible Preferred Stock is determined by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $0.0001 per share for Convertible Preferred Stock (in each
case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated).
The conversion price is $0.0001 per share for Convertible Preferred Stock. As of December&nbsp;31, 2024, each outstanding share of Convertible Preferred Stock was convertible into common stock on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-for-0.6311</FONT></FONT> basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than
dividends on shares of common stock payable in shares of common stock) unless the holders of the Convertible Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Convertible Preferred
Stock in an amount at least equal to (i)&nbsp;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis or (ii)&nbsp;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Convertible Preferred Stock calculated based
on the respective original issue price of Convertible Preferred Stock of $0.0001 per share. Dividends are <FONT STYLE="white-space:nowrap">non-cumulative.</FONT> As of December&nbsp;31, 2024, no cash dividends had been declared or paid by the
Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the
event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Convertible Preferred Stock then outstanding are entitled
to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Convertible Preferred Stock are entitled to an amount equal to the greater of
(i)&nbsp;the applicable original issue price per share of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Convertible Preferred Stock, plus any declared but unpaid dividends thereon, or (ii)&nbsp;the amount per share that would have been payable had all shares of Convertible Preferred Stock been
converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are
insufficient to pay the full amount to which they are entitled, then the holders of shares of Convertible Preferred Stock in preference to any distributions to common stock will share ratably in any distribution of the assets or funds available for
distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the holders of a
majority in voting power of the then outstanding shares of Convertible Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting
power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Redemption</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Convertible
Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Common
Stock</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, the Company has the authority to issue a total of 40,000,000 shares of common stock at a par value
of $0.0001 per share. As of December&nbsp;31, 2024, 3,155,500 shares of common stock were issued and outstanding and 517,293 shares of common stock in connection with RSAs were issued and outstanding. Both the shares of common stock and RSAs were
issued at par value in exchange for nominal cash. Each share of common stock entitles the holder to one vote, together with the holders of Convertible Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common
stock are entitled to receive dividends, if any, as declared by the Company&#8217;s board of directors (the &#8220;Board of Directors&#8221;), subject to the preferential dividend rights of the holders of Convertible Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, there are 15,014,751 shares of common stock reserved for issuance for the potential conversion of shares of
Convertible Preferred Stock into common stock and the exercise of outstanding stock options for common stock under the 2024 Plan (as defined below). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Stock-Based Compensation</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2024 Equity Incentive
Plan</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2024, the Board of Directors approved the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), under
which the Company may grant stock options, restricted stock awards, restricted stock units, or other stock-based awards to its employees, officers, directors, consultants, and advisors. The 2024 Plan is administered by the Board of Directors, or, at
the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Stock options
granted under the 2024 Plan generally vest over four years, subject to the participant&#8217;s continued service, and expire after ten years. Upon adoption, the 2024 Plan authorized 86,215 shares of common stock reserved for issuance under the plan.
On July&nbsp;24, 2024, the Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 86,215 to 2,300,238. On November&nbsp;20, 2024, the Board of
Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 2,300,238 to 8,067,789. As of December&nbsp;31, 2024, the total number of shares of common stock
reserved for issuance under the 2024 Plan was 2,392,751, with 5,675,025 shares of common stock available for future grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Valuation</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each stock option grant is estimated on the grant date using the Black-Scholes option-pricing model. The Company is a private
company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so
until such time as it has adequate historical data regarding the volatility of its own traded stock price. For stock options with service-based vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing
the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; stock options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time
periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the period
June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18, 2024<BR>(Inception) to<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the stock option activity for the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic<BR>Value (in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of June&nbsp;18, 2024 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,392,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,392,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest, December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,392,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable, December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted average grant-date fair value of stock options granted for the period June&nbsp;18, 2024
(inception) to December&nbsp;31, 2024 was $1.43. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock
options that had an exercise price lower than the fair value of the Company&#8217;s common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock Awards</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2024, the Board of Directors issued a total of 517,293 RSAs outside of the 2024 Plan to an employee, a director, and a
consultant at a price of $0.001 per share.. Of the 517,293 RSAs issued on June&nbsp;18, 2024, 86,215 RSAs were issued to a consultant in exchange for regulatory and strategic services provided to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company and the issuance was determined to be a related party transaction (see Note 13). Such RSAs have service-based vesting conditions only and vest over a four-year period, during which time
all unvested shares are subject to forfeiture by the Company in the event the holder&#8217;s service with the Company voluntarily or involuntarily terminates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2024, the Company cancelled 86,215 RSAs previously granted to a board member and concurrently regranted 86,215 RSAs to the board
member at a nominal purchase price and a fair value of $0.49 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the RSA activity for the period
from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>RSAs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Grant&nbsp;Date<BR>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested balance as of June&nbsp;18, 2024 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">517,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested balance as of December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">517,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Parade Warrant Obligation</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2024, the Company entered into the Paragon Option Agreement with Paragon and Parade. Under the terms of the Paragon Option Agreement,
Parade will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of the Company&#8217;s stock, on a fully diluted basis, on December&nbsp;31, 2025 and December&nbsp;31, 2026, at the fair
market value determined by the Board of Directors (the &#8220;Parade Warrant Obligation&#8221;). The grant dates for the issuance of warrants are expected to be December&nbsp;31, 2025 and December&nbsp;31, 2026 as all terms of the award, including
number of shares and exercise price, will be known by all parties. Parade&#8217;s research and discovery related activities has a service inception period for the grant preceding the grant date, with the full award being vested as of the grant date
with no post-grant date service requirement. As of December&nbsp;31, 2024, the estimated fair value of warrants to be granted on December&nbsp;31, 2025 was $3.5&nbsp;million. For the period from June&nbsp;18, 2024 (inception) to December&nbsp;31,
2024, $1.1&nbsp;million was recognized as stock-based compensation expense related to the Parade Warrant Obligation. The warrants expected to be granted to Parade are liability-classified and after the initial recognition, the liability is adjusted
to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the assumptions used in calculating the fair value of the warrant obligation as of December&nbsp;31, 2024: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="29%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation Expense</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the consolidated statement of
operations and comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18, 2024<BR>(Inception) to<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2024, total unrecognized compensation cost related to the unvested
stock options was $3.2&nbsp;million, which is expected to be recognized over a weighted average period of approximately 3.7 years. As of December&nbsp;31, 2024, total unrecognized compensation cost related to the unvested RSAs was less than
$0.1&nbsp;million, which is expected to be recognized over a weighted average period of 3.6 years. As of December&nbsp;31, 2024, the unrecognized compensation cost related to the Parade Warrant Obligation was $2.4&nbsp;million, which is expected to
be recognized over a weighted average period of 1.0 year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the award types of the Company&#8217;s
stock-based compensation expense in the consolidated statement of operations and comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18,&nbsp;2024<BR>(Inception)&nbsp;to<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Parade warrant obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Income Taxes</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the Company&#8217;s statutory income tax rate to the Company&#8217;s effective income tax rate is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18, 2024<BR>(Inception) to<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes, net of federal benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in deferred tax asset valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(16.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair market adjustments related to convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.6</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net deferred tax assets consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18, 2024<BR>(Inception) to<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized <FONT STYLE="white-space:nowrap">start-up</FONT> expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accruals and reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had a federal net operating loss carryforward of $2.1&nbsp;million for the
period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. The Company had state net operating loss carryforwards of less than $0.1&nbsp;million for the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. The federal net
operating loss carryforwards may be carried forward indefinitely. The state net operating loss carryforwards begin to expire in 2044. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the
existence of sufficient taxable income within the carryforward period. As of December&nbsp;31, 2024, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both
positive and negative, which included the results of operations for the current year. The Company determined that it is more likely than not that all of the deferred tax assets will not be realized. Accordingly, the Company maintained a full
valuation allowance as of December&nbsp;31, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024, the
valuation allowance increased primarily due to the increases in net operating loss carryforwards and research and development tax credit carryforwards. The changes in the valuation allowance were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18, 2024<BR>(Inception) to<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance as of June&nbsp;18, 2024 (inception)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases recorded to income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance as of December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tax Cuts and Jobs Act of 2017 resulted in significant changes to the treatment of research and
developmental expenditures under Section&nbsp;174 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). For tax years beginning after the year ended December&nbsp;31, 2021, taxpayers are required to capitalize and amortize all
research and development expenditures that are paid or incurred in connection with its trade or business. Specifically, costs for U.S. based research and development activities must be amortized over five years using a midyear convention. For the
period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024, the Company capitalized $24.9&nbsp;million of research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Code Section&nbsp;382, if a corporation undergoes an ownership change, the corporation&#8217;s ability to use its <FONT
STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change income may be limited. The Company has not completed a study to
assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company became a loss corporation as defined in Section&nbsp;382. Future changes in the Company&#8217;s capital ownership, which may be
outside of the Company&#8217;s control, may trigger an ownership change. In addition, future equity offerings or acquisitions that have equity as a component of the purchase price could result in an ownership change. If an ownership change has
occurred or does occur in the future, utilization of the net operating loss carryforwards or other tax attributes may be limited, which could potentially result in increased future tax liability for the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax laws and
regulations for both federal taxes and the many states in which the Company operates or does business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be
sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records uncertain tax positions as liabilities in accordance with ASC 740 and
adjusts these liabilities when the Company&#8217;s judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment
that is materially different from the Company&#8217;s current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is
available. For the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024, the Company has not recorded any uncertain tax positions in the Company&#8217;s consolidated financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying
consolidated statement of operations and comprehensive loss. For the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024, no accrued interest or penalties are included on the related tax liability line in the consolidated balance
sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of
business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#8217;s tax years are still open under statute from inception. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Paragon Option Agreement</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Paragon Option
Agreement</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2024, the Company entered into an Antibody Discovery and Option Agreement with Paragon and Parade for the
selected target, APRIL, for the Company&#8217;s initial research program, <FONT STYLE="white-space:nowrap">JADE-001,</FONT> which was amended in September 2024 to add two additional undisclosed targets for additional research programs named <FONT
STYLE="white-space:nowrap">JADE-002</FONT> and <FONT STYLE="white-space:nowrap">JADE-003.</FONT> Under the Paragon Option Agreement, Jade has the exclusive option (an &#8220;Option&#8221;), on a Research <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis, to enter into a separate agreement with Paragon consistent with a set of terms that are <FONT STYLE="white-space:nowrap">pre-negotiated</FONT> and attached to the Paragon
Option Agreement as an exhibit (a &#8220;License Agreement&#8221;). If the Company exercises its options and finalizes the related license agreement, it will be required to make <FONT STYLE="white-space:nowrap">non-refundable</FONT> milestone
payments to Paragon of up to $12.0&nbsp;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&nbsp;million under each respective agreement upon the achievement of certain regulatory
milestones, as well as tiered royalty payments in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> single-digits beginning on the first commercial sale of each developed product. From time to time, the
Company can choose to add additional targets by mutual agreement with Paragon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Paragon agreed to
perform certain research activities to discover, generate, identify, and characterize one or more antibody candidates directed to certain mutually agreed therapeutic targets of interest to Jade (each, a &#8220;Research Program&#8221;). The Option
with respect to each Research Program is exercisable at Jade&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of days following the
delivery of the data package from Paragon related to the results of the Research Program (an &#8220;Option Period&#8221;). The Paragon Option Agreement requires Jade, Paragon, and Parade to develop a research plan for each target that includes
design, modeling, synthesis, evaluation, and other mutually agreed activities (each, a &#8220;Research Plan&#8221;), which activities may include performing preclinical studies. Paragon will perform the activities set forth in each Research Plan on
the timelines set forth in such Research Plan and in compliance with a mutually agreed budget. Each Research Program will be overseen and coordinated by a joint development committee consisting of two employees from Jade and two employees from
Paragon, with Jade and Paragon each having one vote with respect to decisions of the committee. When Paragon and Parade have produced an antibody against a selected target, and upon the completion of each Research Program, Paragon and Parade will
deliver to Jade a data package that includes sequence information for all then-existing antibodies and information directed to such target. Jade, Paragon and Parade have developed a Research Plan for <FONT STYLE="white-space:nowrap">JADE-001</FONT>
consistent with the foregoing, and Paragon and Parade have delivered an antibody against APRIL in accordance with such Research Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless terminated earlier, the Paragon Option Agreement shall continue in force on a
Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis until the later of: (i)&nbsp;the end of the Option Period for such Research Program, as applicable, if such Option is not
exercised by the Company; (ii)&nbsp;if the Company exercises its Option with respect to a Research Program, but the parties are unable to finalize and execute a License Agreement within 30 days, the expiration of such
<FONT STYLE="white-space:nowrap">30-day</FONT> period (subject to any mutually agreed extension of such period); and (iii)&nbsp;the expiration of the applicable Research Term (as defined under the Paragon Option Agreement). The Company may terminate
the Paragon Option Agreement or any Research Program at any time for any or no reason upon 30 days&#8217; prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any <FONT
STYLE="white-space:nowrap">non-cancellable</FONT> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Paragon Option Agreement or a Research Program
immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or
otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Paragon Option Agreement or any Research Program upon (i) 30 days&#8217; prior written notice of the other party&#8217;s material breach that
remains uncured for the <FONT STYLE="white-space:nowrap">30-day</FONT> period and (ii)&nbsp;the other party&#8217;s bankruptcy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Paragon Option Agreement, the Company reimbursed Paragon $5.6&nbsp;million for research and development costs that per the agreement were incurred by Paragon related to APRIL prior to entering into the Paragon Option Agreement and other costs
incurred by Paragon to support the Company&#8217;s activities through June&nbsp;30, 2024. Of this upfront research and development costs related to APRIL, a total of $5.5&nbsp;million was recognized as research and development expense in the
Company&#8217;s consolidated statement of operations and comprehensive loss during the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. The Company paid $5.6&nbsp;million to Paragon in August 2024. The Company is also required
to pay Paragon for certain development fees and costs on a Research <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Program-by-Research</FONT></FONT> Program basis. Under the Paragon Option Agreement, the Company is also
responsible for any additional development costs incurred by Paragon, which from July&nbsp;1, 2024 to December&nbsp;31, 2024 totaled $10.8&nbsp;million, of which $10.6&nbsp;million was recognized as research and development expense in the
Company&#8217;s consolidated statement of operations and comprehensive loss during the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. An amount of $3.5&nbsp;million is included in related party accrued expenses and other
current liabilities within the Company&#8217;s consolidated balance sheet as of December&nbsp;31, 2024. Under the Paragon Option Agreement, the Company is obligated to pay Paragon $1.3&nbsp;million following finalization of the research plan for
APRIL, which was paid in November 2024. Additionally, the Company is obligated to pay Paragon $1.5&nbsp;million following nomination of a development candidate for APRIL, which was paid in December 2024. These amounts were recognized as research and
development expense in the Company&#8217;s consolidated statement of operations and comprehensive loss during the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will reimburse Paragon $1.5&nbsp;million for development costs related to <FONT STYLE="white-space:nowrap">JADE-002</FONT>
incurred by Paragon through December&nbsp;31, 2024, of which $1.4&nbsp;million was recognized as research and development expense in the Company&#8217;s consolidated statement of operations and comprehensive loss during the period from June&nbsp;18,
2024 (inception) to December&nbsp;31, 2024. An amount of $1.2&nbsp;million is included in related party accrued expenses and other current liabilities as of December&nbsp;31, 2024. The Company paid $0.3&nbsp;million of development costs related to <FONT
STYLE="white-space:nowrap">JADE-002</FONT> in October 2024. Additionally, the Company was obligated to pay Paragon $1.0&nbsp;million following the finalization of the research plan, which occurred in November 2024 and was paid in December 2024, as
well as for subsequent development costs related to <FONT STYLE="white-space:nowrap">JADE-002.</FONT> These amounts were recognized as research and development expense in the Company&#8217;s consolidated statement of operations and comprehensive
loss during the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will reimburse Paragon
$1.2&nbsp;million for development costs related to <FONT STYLE="white-space:nowrap">JADE-003</FONT> incurred by Paragon through December&nbsp;31, 2024. This amount was recognized as research and development expense in the Company&#8217;s
consolidated statement of operations and comprehensive loss during the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. An amount of $0.9&nbsp;million is included in related party accrued expenses and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other current liabilities as of December&nbsp;31, 2024. The Company paid $0.3&nbsp;million of development costs related to <FONT STYLE="white-space:nowrap">JADE-003</FONT> in October 2024.
Additionally, the Company was obligated to pay Paragon $1.0&nbsp;million following the finalization of the research plan, which was paid in December 2024, as well as for subsequent development costs related to
<FONT STYLE="white-space:nowrap">JADE-003.</FONT> These amounts were recognized as research and development expense in the Company&#8217;s consolidated statement of operations and comprehensive loss during the period from June&nbsp;18, 2024
(inception) to December&nbsp;31, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any License Agreement entered into with respect to a given Research Program is expected to be
consistent with <FONT STYLE="white-space:nowrap">pre-negotiated</FONT> terms attached to the Paragon Option Agreement and shall contain the same milestone payment obligations as the Paragon Option Agreement, provided that any milestone set in the
Paragon Option Agreement that has not yet been achieved and is duplicated in such License Agreement shall no longer be achievable and payable under the terms of the Paragon Option Agreement and shall only be achievable under the terms of the License
Agreement. For the avoidance of doubt, if a milestone is achieved and paid by Jade pursuant to the Paragon Option Agreement for a certain Research Program, then there shall be no milestone payment due for the achievement of such milestone under a
subsequently executed License Agreement for such Research Program. Further, under a License Agreement, Jade would also be required to make royalty payments to Paragon in the low to mid-single-digit percentage range based on net sales of products,
subject to certain reductions. The royalty term will terminate on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis upon the later of the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> valid
claim within the relevant patent rights or the twelfth anniversary of the first commercial sale of such product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, as part of the Paragon Option Agreement, on each of December&nbsp;31, 2025 and December&nbsp;31, 2026, Jade will grant Parade
warrants to purchase a number of shares equal to 1.00% of Jade&#8217;s outstanding capital stock as of the date of the grant on a fully-diluted basis, with an exercise price equal to the fair market value of the underlying shares of Jade common
stock on each respective grant date. Parade is an entity formed by Paragon as a vehicle to hold equity in Jade in order to share profits with certain employees of Paragon and will not perform any substantive role under the Paragon Option Agreement
other than to receive such warrants. The warrants are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated
statement of operations and comprehensive loss (see Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses the fees incurred under the Paragon Option Agreement as
the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying consolidated statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the rights obtained under the Paragon Option Agreement represent an asset acquisition whereby the underlying assets
comprise <FONT STYLE="white-space:nowrap">in-process</FONT> research and development assets with no alternative future use. The Paragon Option Agreement did not qualify as a business combination because substantially all of the fair value of the
assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fees represent a <FONT STYLE="white-space:nowrap">one-time</FONT> cost on a research <FONT
STYLE="white-space:nowrap">program-by</FONT> research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and
development costs immediately. Amounts paid as reimbursements of <FONT STYLE="white-space:nowrap">on-going</FONT> development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for
selected targets prior to the effective date of the Paragon Option Agreement and Amendment to the Paragon Option Agreement that associated with services being rendered under the related Research Programs is recognized as research and development
expense when incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024 the Company recognized
$24.6&nbsp;million of research and development expenses in connection with services provided by Paragon under the Paragon Option Agreement and the <FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement (as defined below). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;30, 2024, Jade entered into a License Agreement for all antibodies discovered, generated, identified or characterized by
Paragon in the course of performing the <FONT STYLE="white-space:nowrap">JADE-001</FONT> research program directed to APRIL, antibodies created by Jade derived from the licensed antibodies and directed to APRIL, and products that comprise the
foregoing with Paragon (the <FONT STYLE="white-space:nowrap">&#8220;JADE-001</FONT> License Agreement&#8221;) consistent with the <FONT STYLE="white-space:nowrap">pre-negotiated</FONT> terms agreed to upon execution of the Paragon Option Agreement,
pursuant to which Paragon granted Jade a royalty-bearing, worldwide, exclusive and sublicensable license with respect to certain inventions, patent rights, sequence information and other intellectual property rights related to monospecific
antibodies directed at the APRIL target (the &#8220;Licensed Antibody Technology&#8221;) to use, make, sell, import, export and otherwise exploit certain monospecific antibodies and products targeting APRIL in the field of prophylaxis, palliation,
treatment and diagnosis of human disease and disorders in all therapeutic areas (the &#8220;field&#8221;) and worldwide (the &#8220;territory&#8221;). Under the terms of the <FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement, Jade is
obligated to pay Paragon up to $22.0&nbsp;million based on specific development and regulatory milestones, including a $1.5&nbsp;million fee for nomination of a development candidate, which was paid in December 2024, and a further milestone payment
of $2.5&nbsp;million upon the first dosing of a human patient in a Phase 1 trial. Following the execution of the <FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement, Jade is solely responsible for, and has sole authority and control
over, all aspects of the development, manufacturing and commercialization of <FONT STYLE="white-space:nowrap">JADE-001,</FONT> including regulatory strategy, communications, filings and activities (including clinical trials). In addition, the
following summarizes other key terms of the <FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paragon also granted Jade a royalty-bearing, worldwide, <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
sublicensable right and license under the Licensed Antibody Technology to use, make, sell, import, export or otherwise exploit certain multispecific antibodies and products targeting APRIL. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paragon will not conduct any new campaigns that generate APRIL monospecific antibodies in the field for at least
five years. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Paragon may pursue the development and commercialization of multispecific antibodies and products directed at the
APRIL target in the field and in the territory, and Jade has a right of first negotiation for any such multispecific antibodies and products proposed by Paragon for a period of five years from the execution of the
<FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement. If Jade does not exercise its right of first negotiation, or if the parties are unable to agree on a definitive agreement, Paragon may proceed without any obligations to Jade with
respect to the right of first negotiation, and Jade&#8217;s <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license will exclude any multispecific antibodies and products that were the subject of the right of first negotiation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jade will pay Paragon a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> single-digit percentage royalty based on annual net sales of the products in the field and in the territory, and a mid single-digit percentage royalty based
on annual net sales of the multispecific products in the field and in the territory, subject to a 30% reduction if there is no valid patent covering the product in the country. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The royalty term ends on the later of (i)&nbsp;the twelfth anniversary of such date or (ii)&nbsp;the expiration
of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-</FONT></FONT> expire valid patent covering the product or the multispecific product in the country at issue. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The <FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement may be terminated on 60 days&#8217; notice
by Jade; on material breach without cure; and to the extent permitted by law, on a party&#8217;s insolvency or bankruptcy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">With respect to patents licensed to Jade under the <FONT STYLE="white-space:nowrap">JADE-001</FONT> License
Agreement that have been filed as of the effective date of the <FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement, Jade will control the preparing, filing, prosecuting and maintenance of such patents. With respect to patents filed
after the effective date of the <FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement, Paragon will control the preparing, filing, prosecuting and maintaining of such patents until the final deliverable for the relevant research program
is delivered to Jade, after which Jade will control the preparing, filing, prosecuting and maintain of such patents. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Jade shall have the right to grant sublicenses under the <FONT STYLE="white-space:nowrap">JADE-001</FONT> License
Agreement, provided that (i)&nbsp;any sublicense agreement is consistent with all relevant terms, conditions and restrictions of the <FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement, (ii)&nbsp;Jade provides Paragon with a copy of
each sublicense agreement </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and any amendments thereto within 30 days following execution thereof and (iii)&nbsp;Jade remains responsible for all payments and obligations due under the
<FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis,
Jade is obligated to pay sublicensing fees of up to approximately $20.1&nbsp;million, mainly upon the achievement of commercial milestones. Jade has the option, during specified periods, to pay a
<FONT STYLE="white-space:nowrap">non-refundable</FONT> <FONT STYLE="white-space:nowrap">lump-sum</FONT> buyout payment on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis to extinguish future
milestone payment obligations with respect to such product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2024, Jade completed its selection of its
development candidate for the <FONT STYLE="white-space:nowrap">JADE-001</FONT> program and paid Paragon the related $1.5&nbsp;million milestone payment and recorded the payment as research and development expense in Jade&#8217;s consolidated
statements of operations and comprehensive loss during the period June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. Jade recorded a $0.1&nbsp;million nonrefundable sublicensee fee under the <FONT STYLE="white-space:nowrap">JADE-001</FONT>
License Agreement as research and development expense in Jade&#8217;s consolidated statement of operations and comprehensive loss during the period June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cell Line License Agreement</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;3, 2025, the Company entered into an amended and restated cell line license agreement (the &#8220;Cell Line License Agreement&#8221;) with WuXi Biologics Ireland Limited (&#8220;WuXi Biologics Ireland&#8221;). Under the Cell Line
License Agreement, the Company received a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, sublicensable license to certain of WuXi Biologics Ireland&#8217;s patent rights, <FONT STYLE="white-space:nowrap">know-how,</FONT> cell
line, biological materials and media and feeds to develop, manufacture, have manufactured, make, have made, import, sell, keep, commercialize and otherwise deal in, use and exploit certain therapeutic products produced through the use of the cell
lines licensed by WuXi Biologics Ireland under the Cell Line License Agreement (the &#8220;WuXi Biologics Ireland Licensed Products&#8221;). <FONT STYLE="white-space:nowrap">JADE-001</FONT> is, and Jade anticipates that <FONT
STYLE="white-space:nowrap">JADE-002</FONT> will be, manufactured using a cell line licensed under the Cell Line License Agreement. A cell line has not yet been selected for <FONT STYLE="white-space:nowrap">JADE-003.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration for the license, the Company incurred a <FONT STYLE="white-space:nowrap">non-refundable</FONT> license fee of
$0.2&nbsp;million in November 2024 which was recorded as research and development expense in the Company&#8217;s consolidated statement of operations and comprehensive loss during the period June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024,
and may incur additional <FONT STYLE="white-space:nowrap">non-refundable</FONT> license fees up to $0.1&nbsp;million. Additionally, if the Company manufactures all of its commercial supplies of bulk drug product for a particular product with a
manufacturer other than WuXi Biologics Ireland or its affiliates, it is required to make royalty payments to WuXi Biologics Ireland in an amount equal to a fraction of a single digit percentage of global net sales of the WuXi Biologics Ireland
Licensed Products manufactured by a third-party manufacturer (the &#8220;Royalty&#8221;). If the Company manufactures part of its commercial supplies of the WuXi Biologics Ireland Licensed Products with WuXi Biologics Ireland or its affiliates, then
the Royalty will be reduced accordingly on a pro rata basis. The Company has the option, at any time, to pay WuXi Biologics Ireland a <FONT STYLE="white-space:nowrap">non-refundable</FONT> <FONT STYLE="white-space:nowrap">lump-sum</FONT> royalty
buyout payment on a drug <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-drug</FONT></FONT> product basis to extinguish future Royalty obligations with respect to such drug product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cell Line License Agreement will continue indefinitely unless terminated (i)&nbsp;by the Company upon six months&#8217; prior written
notice and its payment of all undisputed amounts due to WuXi Biologics Ireland through the effective date of termination, (ii)&nbsp;by either party for a material breach by the other party that remains uncured for 60 days after written notice,
(iii)&nbsp;by WuXi Biologics Ireland if the Company fails to make a payment and such failure continues for 30 days after receiving notice of such failure, or (iv)&nbsp;by either party upon the other party&#8217;s bankruptcy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Commitments and Contingencies</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains a
defined-contribution plan under Code Section&nbsp;401(k) (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual
compensation on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis. Matching contributions to the 401(k) Plan may be made at the discretion of management. For the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024, the Company
has not recorded any expense related to 401(k) Plan match contributions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners
and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into
indemnification agreements with each of its directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or
executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of
such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations
in its consolidated financial statements as of December&nbsp;31, 2024. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legal Proceedings</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course
of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and
estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of December&nbsp;31, 2024, the Company was not a party to any material legal proceedings or claims. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Net Loss per Share</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted
net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18, 2024<BR>(Inception) to<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (46,979</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,155,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> (14.89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the computation of basic net loss per share attributable to common stockholders, the amount of
weighted-average common shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s potential dilutive securities have been excluded from the computation of
diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders
is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have had an anti-dilutive effect: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18, 2024<BR>(Inception) to<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock (as converted to common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,622,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">517,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,392,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,532,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Related Party Transactions</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2024, the Board of Directors issued 86,215 RSAs to a consultant in exchange for regulatory and strategic services provided to
the Company. The consultant is an employee of Fairmount, which is a related party of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Paragon and Parade each currently
beneficially own more than 5% of the Company&#8217;s capital stock through their respective common stock holdings. For the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024, the Company recognized $24.6&nbsp;million of expenses,
recognized as research and development expense in the Company&#8217;s consolidated statement of operations and comprehensive loss, in connection with services provided by Paragon and Parade under the Paragon Option Agreement and <FONT
STYLE="white-space:nowrap">JADE-001</FONT> License Agreement. For the period from June&nbsp;18, 2024 (inception) to December&nbsp;31, 2024, the Company recognized $1.0&nbsp;million of expenses, recognized as general and administrative expense in the
Company&#8217;s consolidated statement of operations and comprehensive loss, in connection with services provided by Paragon and Parade under the Paragon Option Agreement. As of December&nbsp;31, 2024, the Company had $5.5 million in related party
accrued expenses pertaining to services provided by Paragon and Parade under the Paragon Option Agreement and reimbursements of recruiting and <FONT STYLE="white-space:nowrap">start-up</FONT> fees on its consolidated balance sheets. In addition,
under the terms of the Paragon Option Agreement, Parade will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, as of the date of the
grants (see Note 8). The Company exercised its option for <FONT STYLE="white-space:nowrap">JADE-001</FONT> in October 2024. Under the terms of the <FONT STYLE="white-space:nowrap">JADE-001</FONT> License Agreement, Jade is obligated to pay Paragon
up to $22.0&nbsp;million based on specific development and regulatory milestones, including a $1.5&nbsp;million fee for nomination of a development candidate and a further milestone payment of $2.5&nbsp;million upon the first dosing of a human
patient in a Phase 1 trial. If the Company exercises its options for <FONT STYLE="white-space:nowrap">JADE-002</FONT> and <FONT STYLE="white-space:nowrap">JADE-003,</FONT> it will be required to make
<FONT STYLE="white-space:nowrap">non-refundable</FONT> milestone payments to Paragon of up to $12.0&nbsp;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&nbsp;million under each
respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">low-to-mid</FONT></FONT> single-digits beginning on the first
commercial sale of each product developed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fairmount beneficially owns more than 5% of the Company&#8217;s capital, currently has two
representatives appointed to the Board of Directors, and beneficially owns more than 5% of Paragon. In June 2024, the Company issued and sold an aggregate of 20,000,000 shares of Convertible Preferred Stock to Fairmount, at a purchase price of
$0.0001 per share, for gross proceeds of less than $0.1&nbsp;million (see Note 6). In July 2024, Fairmount entered into the Purchase Agreement with the Company and holds a Convertible Note with an initial principal amount of $20.0&nbsp;million (see
Note 5). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of related party accrued expenses and other current liabilities
(in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reimbursable fees under the terms of the Paragon Option Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paragon reimbursable legal fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Segment Reporting</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has one reportable segment relating to the research and development of its research programs,
<FONT STYLE="white-space:nowrap">JADE-001,</FONT> <FONT STYLE="white-space:nowrap">JADE-002</FONT> and <FONT STYLE="white-space:nowrap">JADE-003.</FONT> The Company&#8217;s CODM, its Chief Executive Officer, manages the Company&#8217;s operations on
a consolidated basis and uses consolidated net loss for the allocation of resources and the assessment of performance. Although the Company&#8217;s financial reporting package that is reviewed and approved by the CODM disaggregates significant
expenses such as program-level external research and development costs, personnel costs, including stock-based compensation expense, and professional and consulting fees, all decisions made by the CODM are based upon reviewing operating metrics and
performance indications at the Company-wide consolidated level and consolidated net loss. The CODM uses consolidated net loss to evaluate loss generated from the Company&#8217;s business activities in deciding how to allocate company resources and
in monitoring budget versus actual results. Assets are also managed on a Company-wide consolidated basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below is a summary of
the significant expenses categories regularly provided to the CODM (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period from<BR>June&nbsp;18, 2024<BR>(Inception) to<BR>December&nbsp;31,&nbsp;2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">JADE-001</FONT> external research and development costs<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">JADE-002</FONT> external research and development costs<SUP
STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">JADE-003</FONT> external research and development costs<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development personnel-related costs (including stock-based compensation)<SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative personnel-related costs (including stock-based compensation)<SUP
STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Professional and consulting fees<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other general and administrative
costs<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>15. Subsequent Events</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated events and transactions occurring subsequent to December&nbsp;31, 2024 through February&nbsp;24, 2025, the date at
which the consolidated financial statements were available to be issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Option Grants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2025, the Company granted options for the purchase of an aggregate of 5,566,787 shares of common stock to employees and directors at
an exercise price of $6.03 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Vancouver Lease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;12, 2025, the Company entered into a lease agreement with Spire VA Limited Partnership (&#8220;Vancouver Lease&#8221;) for
office space located in Vancouver, Canada. The lease commencement date is October&nbsp;1, 2025 with an initial term of five years. The total lease payment is expected to be $1.7&nbsp;million over the initial lease term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>jbio-20251113.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/14/2025 4:52:03 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:jbio="http://aerovatetx.com/20251113"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://aerovatetx.com/20251113"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jbio-20251113_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jbio-20251113_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>jbio-20251113_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/14/2025 4:52:03 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>jbio-20251113_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/14/2025 4:52:03 PM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="jbio-20251113.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001798749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 13,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Jade Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1377888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">221 Crescent St.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">312-3013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JBIO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d26766d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d26766d8k.htm">d26766d8k.htm</File>
    <File>jbio-20251113.xsd</File>
    <File>jbio-20251113_lab.xml</File>
    <File>jbio-20251113_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d26766d8k.htm": {
   "nsprefix": "jbio",
   "nsuri": "http://aerovatetx.com/20251113",
   "dts": {
    "inline": {
     "local": [
      "d26766d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "jbio-20251113.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "jbio-20251113_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jbio-20251113_pre.xml"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 25
   },
   "report": {
    "R1": {
     "role": "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-11-13_to_2025-11-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d26766d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-11-13_to_2025-11-13",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d26766d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aerovatetx.com//20251113/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-25-281498-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-281498-xbrl.zip
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MJ9W4^?PXA:>DPSS<"Y>=D,[(S8202?DZ7J2BJ]RA:3S]8ME*UM(>@*.%9=7
M*B!KZ#(9CVVBRS.<D, ZF9;U>B9O1=<X$+$RI5H M[50.9X^BH^I+) ]=(>$
M\Y6H /10 H]C]B:4V9M(]R0FNQ3)WL310J64*/GL%D>J$[0> .9Q$)UFH?J$
MST)#"3%/: R',9+3^B/$ZP:580H-CS98FPMZNFK-!9L.M+(?V.]"#YUK-^D'
M*AASEHH,F=;%/GI<+.;-=&F+,+L>J$],"3. G@9.5VS55 P"52_AY&2/D6BU
MAGW*Q9.*9:T:!(,HW*DT[79&L86!U!V"]H+QJ<!8RM,!6C9JTF 8/J61JVU_
MF@S0][B@W[05]QIG[8HYV<R!%7MKVA>(?)8$JIFODQ1$DOZ68K"H:1[/[P3Z
MC@ND_Q/SF"R\1^.T.R (995!ISY]Q'@<+ \\2D&UX*,/Z_X5*:WMT%>4^E@(
M/&$OHZ2GLAEV47N++#.<+V*%8-"M63J.(N>1_!93OE1,68.8\CL.*=/$92>5
MT$S*Z>7CS#F@P1-W#V?@63R[O<:]R3LI^VM]^:W]H7U/VM=7K2]/B)J]YRJ^
MW8CB,\KX#@Y,(9_^XY;BO^N4WLV7^9GO:Y47*[W;45W=6E*Z1@$627Y^P?PT
M1:'K@87?>6U2+#<;5)4][UJ!'QR-5TPYDFO?8%H?QA*Q0/CG^"\YD0LO2DO?
MI!<*V*]YV\K"RI)*T=H/#^'M)8T+2LR/0KCVR>G)B<M&=L4J]L,!UI'Y"M-X
MX/S=2NZP(9[+ZHM(L:80X-0I\NG3K:Z:8 $FY?5MO9ER[*['G6P10X_+ 1H2
MNJPR[T<F(VXBO2@9:[68C+<SFWEZ?U$LV[0L_G/I8[\P?6Q#G\LX;%OH%(+L
M+=E$WG-4MC02^Z<RB%6N[I$_FB",4E?EZ L.I(E@<;>$ZIB5Y)$4KAMG%[FO
M:6B,+\'?UR)N? GZ8<9*3L*&@VRM$-C.?W:YT*M>L=UI_WI]>?_'7:NS]YS1
M[=06'>9._HZX3#7+[/;[T:(Z1S?RQL2AD=([A%S%EZS$I0P*EF;,">:QNZQ/
MO1[NS>% >H\_;H!IE0@SCGHX($1?2%B%^U3*Y+N/XV8CMVD>KNK@;/U8;MDQ
MJG6'6=S[>$= 5"<!Y8QO_C(J>[W3;,^[UV_' S[GTC*SUXE#9PV_^<;\<L!>
MKV7[(5&>3^\L.]S<?T&MM,2!T:^F/9C=-GLU2NL?:ZG/1@S5Y$=/]G&IYHX'
M;'P8U_<!Z#./P*VH[WZF?2^I$KD']_VC%'V(M?NO?NCM.U )^FSC?EAAFA1O
M9'@:67C.<3]T:/8YZX%CF]SP>:-O^)3KQ$47)?-SO?J7?!O_#U!+ P04
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M<.7!G3NT0:0+I@9W?UEZ#YCX-P)A<G6:'D5%2P,5W],6F7?EO=WBWH@ %AD
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M/1<GT@YVW)BM'[5=:>.,X<?(]-BE;=)Q@ -5@O<H+D5S,1[Q&<Z$HBH^>>7
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M^G3^%O9Y>?;_.*<?Y%^_7;Y_>_[I2M>]O#U_=W%V\;D)8VV)S%Q]&"OPN1#
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M@[PLM81_M#[X^WKG[68:P\.AN?G3& YJIC%<?8;__ $0=B[?.9<?SS^=?KZ
M[ZG1PMGE'Q\_G?]V_N'JXC_GSOO+JZV:UM ,:\AES,NC18<UO&SF*RPUDN!C
M/J+UU9M/KVLBCO I(*\UJ!4_J00M^1_-((/[]@LT0T=U??-&Y!YLCSMAE67G
MB?+B/C>3'ZA;%41C5)0VI%ID>5/= ?+</UBR#GV;?>NKPX5?>?PD#QH=X(C
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MJ=J)R9D$HST8D*N4TPPP:Y0L!JXV]MHM.S!-=F.<L8->?!*R4U'V0X5 1?^
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ML_MF0'I=%?/3KU[ @L=2(W9J8S[+.#4=Z WD!PQW^XYRR7?\O..\L2X[ZK,
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ME#T'4+G'B7[)C2=SB0O$K/[!N8%"]EA,[!/62!(5EAT/_%L>0$RC^;0(UAH
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M>OL:SKFHSKMVCOFD*&K;_8&/W(SO,PB LRQEF^/WJ)> ^4>5MOM[W1=BI_(
MK<2_#JFA/^:CB94AUDT*U)[JSGJVX=)N69:+%W"Z!%@N&<[KRVC"XQ56342A
M*!PO#K6]>H&Z90C/?((5P@RMT %Y$[HG+W$&(NP8%D5I9L\SQ!_EHPO)]H,#
M4O=&=M.$:'+E@]CP&X>7J25>^/^PP-B;J)B'&\IL/2YO,QDBW*9ZA"/8\ ^T
MC&>GC&@8L)4.ZXX]8)&P79#+61S+R+(H#!DZ/,T-73<I=26#'_:R!"QQG,!V
M-59]NI@ #79L,\FNA#\[5QV'<QJF;L:::3C*$G($Z&-((\DA.C08@/A& )XS
M\@<$-RKO"U-[R-]JG(Y%MT/?2L1YMG_8.2EZ$DLH5YN>LP97',\O):0MH/C!
MRWW7\8< 1E#&T/-&]TNT<!V1Y\V)[D) MQM_+'3F2B]+\W/3!D4/"P1(9MCU
M$FZ>DPW;K1GIAN-8[?+*.N%P(8]$1+ZSN<F,U=7)XY2FL=_+4F8:T7"(9<&X
M7QIBV=?%PZ24BG\V\$>P^J#L@4[(8X59.H&B]J9.DF:#"35"1;\6[-WX^:JP
MI 6BOA 9(*W^+?X__!:PO:=4".00I#Z\HK)" IP01;Z-HCW5!VX$6V'061<+
M;R.O,E-T&1. ;MAC6W+;E-O=" GD>]%>1095NX4S:?V!FM9?!R@UC:/ I=_#
M15Q?UT,'.P8YWF @$RF'O#ED>8!D$;J' 3\2!)O7AP\3GQV7Q,4(=/)3&H^*
M5Q2%(A7(!:?G[=)P5O@^"P8B8O#@]?L93KM%.+1UC0.D'?I PY W[SH9CG8K
M.L/G!R]BP?82ZA8Q4U\"'V0<I<@,D0M;A\K]@@),7#&?\JE=OG)A:QJG:69C
M3N_09&_;)T2]C8);A=@-K!F@2!(J \*(T44LO^&&ON-Q8,T!8LK]RBMZ=PGK
M";&ZEAVP\$*/N@GI4 \0XD&XW@@ICD(S] J^ YL:^6I58O!"RTKX><<YO3IS
M7ASNZ158 MOQ$99=7IB?ALWDB-%=(X'5<?D.QT+/\\43!>@U9"YQNY6 U&67
M>C:F_L5P3:''Y&>&'2,^14'&T,&.VZ$UE7@\5IAE#&?%JY'VT6#3]Q4R0U="
M,CQQVD2#5/\F1(W!&0%)IR(?MS(6O=_$HK]5+)K]1<D4.J ^:T66 %(!G^ H
M _(#36M$XMPD@II\)ZKP)-%/'=?Y.QM<<P&,R$<2+,)=!9>M8!]\$L)1_!!#
M@?P1DA]H)+=^E"5 DB9XUW'>@,Q&I4F6$;;$@LY)4 _A;Q)59&O2YUUBGQ9I
M$F.PQ!G@T@0WWVYQK [%!]PZ2P@=;!5N4RNT)0RHYW/KG19:S-M\RP(I*4VP
M<SNFJV>AQVH8<.]X+[$"4\@LE?ZCZ"$L=547%=_PWC+,?9#-%J!7'H&K*(/&
ML8D?3L/6::J5W2(>%#5 7E\ZB5&S^'6-N+:)D.XZR4=BHB2$&_$"HAZKX<HT
MU-"!^;I+#3 RKD5UO\^O!:'3;CUH+OAJ;SV,<&]Q1FJT0 %>D /!H[P+";'+
M80U@"BJ7?=[""7M>@)P+9/*-4D8FKNG:AWZ@6.N*%>B-S&T!R$D?=%'<[,2D
M=9 2);SA[RSVDX'?-R@OR0>I48I(Q2<E&.DU0.4U)B[8;FDUJ4ADP+>2K/<W
M< Q.<3$*"NY!:VB(!9PM4]@!:L@4;685D-C!9_XD-GD.P WA>LDI0C,AOMHO
M20KF7T$=9:<$+@0,$A,=8 EQ*G$?0,589S!L-B6OJNUJ=Z]#<SVN 4*7]%[G
M]#I6BJ?/<0_6>JR:UH)UV1V\NGA=W$"[9>T@'QFZW"X>A-J <[]G<-%5'DZ:
M$)-UA$KW*0C97@3V_%L_Z:,':D+(588DZQ?ZF/@+:=AOLM\2)5(NA;.HU'5.
M/WZZ>.^632Z#4ICYA9S?.)- A[Z.O9$[W^7Q^^G;\]V]O:ZK/1Y,=7>6DY*,
M_W%*S(TY'QYW +N[BXS%3?-P!G!N8*%FXVP/63\I;Q!DH#<R9:8S/3^RT7V]
M3X3;HJ<[Z.BGV+6EY]?4X;GK_(YW@?*95+2OP)A)-G [?F<'+EH\MORH]MF2
MN>(YIA!Z[N86./1'!M-N;[*KUY63Z /)+]A&<HG-(58*3CJ)&GO46]BKQS[=
M+$5_CD^P>JKBD>7C7<AU%JKK"/ 0$->^)"]-O?Y-<7#0-1)VA2X\<B&JKS=^
M#[C^CJ?A_-[OD[@WO\S=Y!?#(D5^57'?IUPE5!S&N9Q']2@P@WJT> UD92^_
M?3^UM,W<83[ROBP A3 *=T%'!4I @:&A,$*!F$8ANIA9KR8M5=\!0#L;XP?/
MNON=O:*'F&6" @ B[8RE35-^F61YL_ISXZM;H^5H/;(/*@,9R[9KV>P'$$:_
M>6_5;Q:O2!1/VBW[A7#)=PIS$0$&/K'/.)J )C1Q#&Q$PUF0@&;\((CN0"[L
MCOQ!B6HP&A"HW8%_C7B21U?D2$,_3LA/.T)T0I7:"\B&(7 (*"E?+AID_10T
M1C*$_!$GS<%_)=TNCP/ 5=Q$P!HU[[28HN:5H).,LC1#E:266!]?J\NY);,#
MT=0L:C%2##_BB5Z2SFHA@HYPY $;3&T5&>DZUS0O-06884YJZ@\G+JOF-[!X
M'\W._P+P0PH=D8_*TW(6P#H@#3B!Y6(S)4V_F:&)IK/L#M0W;ZS XNT;H,.1
MC%8.CQ+OW\%KACUH_F-8NC#;G/V@?J?U%+HJ(17BPX@KY4=Y_ADQ*<K#!?:*
MK\R[R4>!(M" ZDP^^)0,0T*M01:3EIE;)A7$945 .Q0L@&?F)KTDB?K$I*N;
M0ZB++@N"@&-S\+LP(]$/*PZ\B4Z^E*U@F#3P2=?1V;I>BOZ#_A<<W$9:K$:2
MT@0Y*Y,8_ZSLIB)I'<Z_*X)_FAS7W#LA !M,=6V%BS*LB9C9-2.Z"=A2I+C0
M#3*B2,XR6VD)'AICRB[@(QX_O':=9!*BQP6%<.[6<:WH4QD;K=N9CG"PE5R_
M8-7,CGMZ$[TGG46.UP*RV/!]##"14T7#B82;IE'FWV8]E/WP.<9KPS+^(E 0
MS8D; #JB+5IZ(LDJ3^#Q*1P\ BLJ=ZYY%6CTL@& N>.<UU*-ELC(,!(,<;'I
M3KG>; ##0L[?$9!RL?D,L' _3972B@[1RI T5P5;BB8*#L$&/B($^>DKW[5;
M!GEH]^:G&J8$JAOOEBE1.;=1*@>U^,$ R"G1;G!QV_'F.LY?Z$6LL0@H,,52
MALL##.OSKH'#H3_%J1@+^+R1SA)L%(Y0RY/<NC<CQ UM&\[H%:F[0!2PD7\R
MQ0GEN4.-# "X/-A+N&LJ-^08OH1&[ =L1DX(Q<?J%,FX J1<*'LE%,0=+&P&
MB8+ #B1;,>9&@J#41$3M]NU7MT) FW)A9,K5.9RKU+/%H8V#)K2Q6D6,"]*H
M@H88'F!)X*/V-,N6=9(;I#T,H?N8A^03-6!E$Z!?N[6LJ;HZ0Q7TD=0GIN"@
M2H"ZQ<_.CJ^G0J+='9K^G07A3^1<(A7-QM!^--XZRE2A'\KS/CG<L;Z+;43C
MB!0E_1?8@-Z!/\NLE/7*_-VKV5$OD^"I%QM7;Q:2Y@=/:)N4]:ZOJH]^/\^I
MF+NZUNQ@CQ0P5QP38S\VJAX>%#!XWC4=[.W""OI*1(O<L7RD5"M5$LV N.@>
MSU\D#S[_A38.4"M<7&%?5A =#VT@]!DP&12\/,,DF^N8>5[,IJ%T$$T/K)9,
M)0.40?!(5=^UM.NA_ C^$T984I:@$8QB5, N.CIF@&#N38RBFX)TF!"2F_,N
M)Z4/=)U;H0H-\]3 S#462A92\MP0-0TIN=*'H%>S )13LCZ9F\^XX@(^)/1)
M]%',!('ME,BG@B9R6OAVDB?Q 7'HK4S)YZN8%P3+G$65P9WKH(6[F\W!\%8J
M*[5;/ICF Y\+. E2U?LH! *&;CG^BA][?")XQ]#S TIQP6!-6N(,E-R(!QX.
M:1H8NC%J69 CRHX.EDZQP&KH@95EC =DR9C<KBY;R,RY,4^HW2([XLY/2,7P
M)ES_B]E*VMD#=XE,!!TUN<TV@C5N$M&LD1%-C'.3DJP)5HM?1AT=T0T ^UZ(
M5(0KL%%$^S'6KX$;BGK*C/%2S*_!ZDV*Y6>Q''HA_U MMQ.697&LNIWTO/!+
MG(W3_F2-7A=C=]0XJ6WTC)4_ZF$H+-=)GQUUCJM5ZU.333GSEOC56&-I+GT4
M!R@K?,&RYUFKY?O6/FA4],D-/1.G<@.9-@&D7?,FL@7&8S T:^,?MF?I)HZR
MZQLK7GNPI^MW+Q'S4/D8@U5''H*9X"@?#PWTE%I(8>^"H\Y1$< 8,K%"V/37
M[-Q><70:-V%]8'_)V>]5+]$*FRB0M*KBEB6VX$BGV37*N>K3.-\P2"+C5P>I
M'9$XU \CCFIF9L.+Y".?-^&$@.7C+*M37CL+19'2ZL$ILWZ,AB7R?JUP6)[@
M*@[6$(/V \FU!A.Y5M?$YNIODG$7$]&[>YV7A0MT$;5X5?SR^&D@]FF(!0,9
MO__909F>_23/RO!S9L<25&=TZ"S]G(VU6SKYJ9 FEG>+F D32>1P*(]C3CN"
M>V"A*'W,U&S*>];M')3EA?;RBIE2T.DKSM)V2WAD'C\F9@&'_A#=YK%C +O!
M]W*3ACD;/)JVP3 R>1VHV!7)2(<(B-ZF[E'#..=:B1+L2%@ 3J> 0J50.>%L
MHRE@K=EAY-,UJLO,BXYG2^=%O7O[QKM7JV.(YC MC\MBD9W#%7'(1T>/=NO^
M'++;V5\)AW3J&.1L5E?50?;*_ JC4_.19*D4$SC393^-%F%=B &S>-?>--[%
MX>8Y#%9S+%,U4N:J!-RI_ QMWW9+NPW^__:NM+=M,UM_%Z#_0+3)A0W0OI9M
MV4FG4R!-EYM!V@1)9WKO1TJB;=[0HH84[>C?SUG?A8LVRY9=:X "&4LBW^6\
MYSW+<Y[# ;0!1^NKZ9)U3Y8!V*RD.>__9'0[]Z<YMX6O;%:<W4[]@&Y,<Y[8
M([&JXL3#B_8OZY&-:<H[07SOVY8\JA9ZKJPI,6WR1%,_I[O4SUU L!+FV^8E
MN9(^\*](< .V?$?.O06#-2[!)=(J-9CI([L%5U1ZW<XCO07?@!35LV,>#+N>
ME;N$!1BW +$F!FJ !8W5G/^:H%?&RK7 7IL#H#9/&\G&%UB4;7"3BHWTLC82
MQ&]W_OU$%"6@S .IAGT\/\H<2'$T5RK-XBF7EPO@DT/I"<H5%\D*UP8F1NJ;
MQ#,<9R"*8ZS@'BAPE&%P6!44S>C?93/H<(GUR\;IK/+@EH?)^)SB EOU0Y0_
MD?!_(B?*5$@/[.*A/>,N ND;L(@((S,!JZQ$II%%&^\G;^K)XZF4%F)6B.8W
MP,J7!J' S*$F12IH7-H-^PO)TV'MKNJ^=*:IYU'#MK5FV['\/\?!A?K0^J\%
M2G]+->84^6T"5=?@OWXTF3 "V2U]/1D=N,A=5&-H=B 4*:?:>J8,R9BG$D&[
MM.,"TRU"FK>FNBT^%3^T]3HZ'A08MK5M=HPBSW</.,N ,. L_ZS$F]D"O/-[
MAGC_Y#-\C_RS\AX!8RA83+$8#0"##0&RHV**B&QF&ZX,Y@8N>)CV,(V2:S=@
M"E<QG.8Q9LY)-U/6DHH^Z5S#E7Z!D,+Q&%%71621J*TP;@8Q\,H;G24KM(6H
MF&\RD?V23Q?I/2HWH2QIFTG8)]W4^-&9'DT4;SC.L*J,8.MV;J,<_S\=0\-Z
M$3GYY (;#A5(EX'8]2Q (K*71+[H IF1U6,:,998*4! !PV_B!$K2&&3#N9!
MT/E">MX9G/"TY(@X86H9-CHV4!PAXC"CH/V.DAPWYPL<?H3@.F7'H*%2K S5
MT<MP23C0=^:AZ8HZ!0\\+ASIH8+\$BY3&4^%!>/:=X<)9W 3@S'**)^K#+2?
MD(N K-%K$P0=C!A822-"::1B5YJGJB8+0X7QNG!#PWZL0%[BE0"=/D6\X0TJ
M,>_R:Q,B=3:([F&*F;EAC#^G Z&2P&K1R$64VPIXT"MPI N&B5.QCZ&GLC5I
M9/<R>H64C"EGQ86DPGJ^#6C[>-\$-R,@,-D33/\2O)F,5Q$)AWW&^;VIJFXH
MEL7-7LENWBOB./@=(;VO]K<;^3$1 I+V.';R@XOWFH* E0H ]G4B-[]O" W<
M0Q/G-\DP5AJQ,3&*'P:?44K4R:&J6"L,HK\7TELUE6_?Q<O9<E(#1FZXTD6(
M];H:*%G*XIT"6<>%(^.6"<]=TB(N3!:(DK-+S(R.;@PL"JK(A=<QK(*PK>@=
MW,ZVIK3K<.:PHCTEBCO2-<(.5!;Q@HJ,$5C)J+109R<70K5D"&Y@V -3GBT$
M%T:E,1[14L([9YW_P@1:A$H3^Q(# ;@=\.9<G9.I5]&IU7]2)Z@1!&?U0?UG
MY81NO00V/\JU1"EAMX5>*6:CKIQ3@T-'U'W<PAT!(_T X8BZ'WA ^5;,?;S#
M I8T!334]G7BP7#)!1FB  A5#W_)G'?&#&5@!D@.V[(RF-)0WXNFLUM>V^4>
M(]T>6M A^S(8PN,3+XJ#G"=]T+C@^(A:0.UY5L%'6!S@8?#&>V)A8^3L5\#C
MEEC_ T+XZ[I5WQ@RG([:1OB?X&;S%=B,YW 47CV$+MC/VRS_XM##45J]4MY1
M6) 5"?/%A1@JKC$UUU=^@V7=[-XO<%!YB^UMP64**AN#F&6&;P-'K6GHK.HR
M%GCA+Q<&0Y0VQ\&8GTJ6[&FW8*A@]G0=NAUDACRK!6J7NCJKN%RS.R;VXTC9
M,C:"$)6M6C#3$#IPT=T#&/SM_A.N9^GODAIW9_:XNU"Y%" M-MZ]<(!\,&D.
M'U,J;K07@6XJX- J.*?N3>N?$>FM%= C4P*=$.3;*X'&HVQCM<:Q$0H<M_YS
MK0-<LQ#<0CS%O]KA(]N6%%[2$H!F23 <:BC!Q+@:56O]&A]K2NG%KC F+%EV
MIN[.YZ[86VJ>4E*[4+2TS+9&B;'46^9F K0V7GD2":-OPVJM$9YNQXTELW&J
M7Z:X!#Q5RC(E: G:),JI0!%,B70$IST.'8.70N7E@+>&+%@U@:MI$XU )$J3
M#-:Q%WX+F\L]+<@'J^I3-%TP0 .["_()+K\X0T[*$>RI3$K-AV#$NP=$!$7\
M*(:82SFV2YS]7B7-\._\@1R169I=SLRN,LUP2"%G''N:PEG#]F%37"!"EINQ
M4XD%_#'-L%&1D@DXXZS*M!5>&AU*JBGSY$!DG(XD$CVYFJ71UX36,TW948"=
MMCSD?$BB2W@=LUY>E:"#4%_$%(JCCPL*'S%Q(5?7&F:#"*MYO 6BUYN5H/B1
M2H?W/1#7/$'&#EMAW\( <7=-+IH3^?9:<\+"37)<8T4Q87ZS(9ZK2BVHE'W$
M8SNQM*11$] PYCS*4GC29?+-8^XV1GF2>MX&9DX]$"NC,-%X#E^/LD**UB.1
M!#B'U)".B!H_4GRVA\S(48I)+#=I7E,U&]PWHJI@OF 7TLZSQIPA45E$Y?0J
MRXE7F<(UQ.4,$R?B#[H12>78D+!=:CRKX_("KC_.6TN\1V+Y#A1@=8XKEYW6
MR$E!88)+XJ&_OB['POL+4H-57\@=3?OIL#;8QQBZ!=J&8K]"1BVWF&X-^,?8
M9@W)B%A7?HEGFSY?WU5=)6OOG*W="6VS+<V<7FG5EFK5EFNNK:N]/<@J#OX>
MM'5M,5T^Y,?]ETU]?>3#$["AW7XM:E"S;?Q?W_9.7S?]K%?Y6<,+W ?56\)X
MGZ[2OF.EAC0F=8 YV!4LAZ7XKHQY$1IXM6]C<)4A'AZU-JPC.N_N7N;.5K;S
MYBL;F6Y7O;/92;7]3;2[27-;P=U9>JYGR:3@X%*C/#)&=9!.>!A=@SUPJ;T%
MU+<3B[#-C/0L17(7IT$*AAQ8";:-29ML[M3\3C0=T<3R>O(<XZI-U6Y$+:<K
M*SZ9%'VI4^;)L# _B>O ?@4;AX9?,Y*K 5[/MJYZT(8XB++:B&!::G3H766%
M'_-DD)6$;^E%IB>0"554S>3E$9_M]A=14W)D!-LXH*(PT 5,G[3//"2Z 6D[
MTL@;0@$%S@I)VV^/FM&2))$@8()/@O=9R6K*11$JM1-^S@6J$@(PN<N64>I6
M&LC':M:"KIR-0*0IARJ(7&NV[.V-.I8 MH2:%'B7 H1;AW_( /N=*MVITD95
M:M%1;D BV@0H;RE24@_:*(!$$_6(QF,,JGD81](6>BB65,34#FVYUX++WOY>
M_Z2N,@J7>2@X.7IIP9BB ?.8>9L8'*@A2 J<&RR[Q?%)1-S"^'9F_.Z -Q_P
M&M(W'H],JPF#@_4HR5J0IF2@</8]KS#+6 @MQ?HVBZ&M: ^&U"YQ3B2CW7AH
M*X<HH-XO8$?N3M/N-"TZ31N #$A[,H=## [DF<\IQ2Q2W8XD'O\6D)WK\T:I
MK8M\44Q2IW"9KW0N)OB"J:0OT^A6J/M]"J@$,8@W\7A(_%]50JB=Y;@["HU'
MX<]*)I55<6'SX>IPV2#HNB?'*5\*;!]+JM'"'CPC!VK?C!/;6#J(+&7)[LAE
M@XTG*)[,V1.J1F-V.LGE(*D;+(U66G%-!B_68="VBC2O;L?"S.]O8EZ@;YVY
MP7^2N7/GYE"?4DVKT@5'R@GEE;Q441G=#A;<&8)AD:50</><D;S;CF#@O+8=
M.XVWTWCS?66N4"0%9",O4\DV6=")1X2Y ;U7+7(U!KL4Q-0:O* [66MZ0WP:
M<N(H#QM25#^QA0;8'R+7WF0;5#+67^#:49Y,X2@?8LL?9I,9]3DC\Z9Q7BU'
M]"F"+<^> ]CRKZ'V7C>JO9HBNC?=@X@Q[IT9*:R]X+B1< %8VFR'4,(&_.FK
MQ ;L$5G3853>V1II(T<%^5T$&G/"Z8CD+RV!ZR82";O+=W?YMAZ #P]4D<YE
MN-V.HK]JH#US*1%EI-2L,H(OFL SOU(CX'06O#@^.NQ5Z$?QH"F3=P.+@5/"
M;=%\AWZC/B[B"I7EQ'8OXMP?]\;#@2X3Q&_NX[8X-%=>3PZ*\MHL6CG#,(0A
M[WC(O>*.IVC;ETEQ)45Z3BNV1DJ1*@S8+91?0A'=>SG.NQK&4JNXI60*4ZM<
M,27IW&1:5.K&/$+0M>RXB=,NBZ"?E@G-5C_5X:7UI6?+4DJ5.=\[TTZ(RS $
M>>G7EAKG8EURH/7)T.3VU,;6R$/E'_@ SI<]7HX]2U7-=_ 0NIUZ4/&N:WEW
MFJ7[(6C=5-/?[]_]\!99L=YC<^FY%3</V'3WP[C;^24>Y&64"[_U"7-:S._
MJRUKU67C(G><';7.KGM-+OQ]SBH8\#PIR#_+_TV"'Q,$*2;#(GB'1WZ,[#G7
M";YO3Y[7_+4F;+UY<X/\5JG^B:!AM,Q%T@C.=.&=S:4@3O4'R'O[).B@5&I"
M%H[I"_SCX"J[-</!S>EV<'?"8""OB6P'#3YE5.-+_P+U,"J<OGTN2!R>0/$'
MYR\C!8_*!SAK19 RGO1+'$]"#Q(55PI!1C&,)P'+HBRT4X\/,W6++UPL$C=M
M4W9,*M8O3(32SML)#0]F;;)5UF6EJ>32D>96(95W?9216GE<^1[$(A8#Z$*
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MK"0&*PC!V:,2@N/PN/^,2I\W?6NT%[H@EE8MTA6DX_Q12<?)!IR9)Y+8?;J
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MON@=GE<*_F\$^*XOX$?@:YZP1N[-U\@@M!]^^C_XX__\\=O['_X#4$L#!!0
M   (  4X;EOZ\8NW0 ,  $4+   1    :F)I;RTR,#(U,3$Q,RYX<V2]5M]O
MVS80?B_0_^&FIPV81$MN.D2(4W1+ P1(T\)-A[T5M'1VV%&D1E*)_=_O2$F.
M8L>>DPSUBVG>]QV_^\&C3]XM*PFW:*S0:A*ER2@"5(4NA5I,HL;&W!9"1.].
M7[\Z^2F.X>S\X@IBN'&NMCEC=W=W23D7RFK9./)@DT)7#.*XQ_]Q_17^;+WG
M,$6)W")D1VD&OS="EGDVRHY&OV59D@Y)!KGW!B5WF$.:LO0-\TAXDQ]E^6@,
MGS_"!VX=&@77HL(A5]<K(Q8W#GXN?H% .M-*H92X@G.AN"H$E_"E%_PK7*@B
M@?=2PM33+*FT:&ZQ3#JO2UOFMKC!BK]^!4#I4C97Y+*I)I'/0Y>&Y<S(1)L%
M*YUA;E4C(U!,*#2BB ;4_^9M<:@.WF+7Q#FWLT#J+2$] \;WF=!K-$>C;RF5
M;AG*XZ%IFHX'\!+%&AT$62R2A;YE9-AT[>WB\1"RT6C,J!L<91D'%"G4WWL8
MWCRCQA@>LD6Y&P=">GQ\S()U0U+I'D;0>3]BK3&@N7-&S!J'Y]I49SCGC216
MH_YIN!1S@65 49=6J-P#S$.$XV:![HI7:&M>X!,23<WT6%0D-&5_?;S\$OHL
M.O4$@-!ZHJJU<=!VX*4NPLW8DTS_*^YK$/NM.,WB<9J0LPC4EN8]!03V8B%]
M:9\E9-T7!PNQN_K7+V*_V'7ZXUW_[ QL7F8?_[&//WU[4/Q;P^!_4*+5U4O%
M#";:\VNBN"C:@=4N#Z_+/?-%O=G/!)^'_0=O#I'NU' F5TJ[<-!0":]KH>:Z
MVZ)-W\1YW\E3G$,87CDWA=$2]X\X5AM=HW&"!OS]96@=W!B<3R(_Y^-^SGR3
M?);0G.DA6P<\O%[>S(B"\O)>7L]UPGGRI3>#M]-+R>7:M6^'260I[W)P/7]P
MN+7!IX9+%$NS/91M=]2?!Z@G!^_/N28$^,77Z<6NUV']/##'EUKI:M5*/--%
MX]^?_ON]*C\H$K:ZH+XR51 5@:!W9$KP;P?!UQ)[D272OS81FC<=^0_]J>L]
M#)=<E="Z@X&_$[;I9--_8['\I$[#NN"R:.0ZY1VY0^PC;A;K<.:]LMV\;K<O
M5W^)V>8M[G:&M[W=:J<-_?P74$L#!!0    (  4X;EN<X*='S08  *),   5
M    :F)I;RTR,#(U,3$Q,U]L86(N>&ULS9QO;]LV$,;?%^AWN'EO-J"R8[O%
M4*-ID3G)$"QM@L;=A@U#(4N,0TPF#4J.[6\_4G]J.:9D*CQ6?M%6D>Z>NT?Y
MG2M+IM]]6,\C>"0BIIR==OK=DPX0%O"0LMEI9QE[?AQ0VH$X\5GH1YR1T\Z&
MQ)T/[U^^>/>#Y\'YY=4G\. A21;QJ-=;K5;=\)ZRF$?+1$K&W8#/>^!Y1?QX
M\@7^R,J-X#.)B!\3&+SI#^#7)8W"T>!D\.;DE\&@VR\G">(K-0C]A(R@W^_U
M7_=4)+P>O1F,3H9P^Q$N_#@A@L&$SDDYER\V@LX>$O@I^!G2I'/.&(DBLH%+
MRGP64#^"NZ+A5W#%@BZ<11%\5FFQ[#(FXI&$W5PUHNR_D?IKJGJ'ER\ Y$ED
M<;KOM*-.17XFUE,1=;F8R5Y/AKTBI;/-6.^EK(9I0O_MV[>]]&@Y.J:Z6"G>
M[_WU\?HN>"!SWY,G7_ZR@KQ,3$=QNO^:!^DY-&@0*B/43UX1YJE=7G_@#?O=
M=1QVWJN"^=GQIR2ZEEN0>A@)'I&:PNIP6KV3QR>;A8PGZX2PD.3*W[1YD$<]
M"'*?J2KT4LF8!-T9?^R%A*: J U/;:@.?Y0_?!US2?O9-$Z$'R2[]2)UBK@H
M=J8F3CN:I-YN0RKN3 0[6KX("AVY><!_'M$+N/R]+1(O52S2[P6?:[O(RW'-
MP:_1--*VJ4B26VJX"?.^W!WRF@F5C0D2\Z60>#7YU:9^WJ?*\$^A_>^[WK;V
ML;0J7T)B<MVT7SLD[TBP%#397*R#!^F7?/+GQ)1,?6Y+@-8:X=4Q-KA6ZR%1
M6Q2 H@*H$M;LNNN[C'#3YNU /IO+UVOY)[F,_)DIP4^26D)7WSK7'+2!52.$
M1.DW95#2UG0Z:+2,I6FW=CA>L$2B/Y9EA!]=R2N)]>]D8XIE17)+>-9;X35!
M-KC6"")AFU6 O 2D-4 6L0;88>MED)OW;X?T.0^6:FXFLGM3DG=S6@)8VSC?
M/V:#Z[X.$J6%,"AE:S3QVRP3:=@K#H:W1% >7K#P7+XQ;\KCD^26P=1;X35!
M&*AJ!+&9S4J K &J"!J^#EK7<FS</\;%PF<RH^K='DN:O G3Y[9ZJ5!AA%?'
MV%\HZ/1PKQ.V%7#>A+GK6W.18-P\!LA7+.!BP45ZS^\ND8,SYDMYD;(9\[ A
MUP>D6L7<S"8W3K$? @-YW)G8*0AI1<A+@JJ)-"3?P9=F9IYO#F.(+FE$/BWG
M4R*:34PYK]7QT!C@^N/VX#_5PJ5<J4,FCP0T=K\:>HV:Q@!UXJ^O0GFQ1.]I
M]I3G.=16BK2*\"%KW"#8'NY:85S292G8K87+O5,KFB%XAA^,D3@+0VD@SO^Y
MIHSTFXV#5J#54:BSQ \$VH] I2@N_KG^JV(#5"6X85C7,<YL:-!_AA<WZ ]L
MT1\<'?H#4_0'+M ??#_T)RON#'TD&\;HUWIQ@_[0%OWAT:$_-$5_Z +]X7=$
M7Y+@[G4?R8@Y_/5N$/$?R\T;,>$K]BSXR^G'@+[&C@[\;1@:]D\E'4&OR@ 7
MH KAXHYMH YV,Q>(F*>W@V[$K>"/E 4-[VI6:1P#\%7&=-0_B45#7ZOKB/_L
MOIY$IZB&.P1.K-1-0@,_B.-PR^/$C_ZFB^:W^/4*QS *>E.Z0=B)1!L#C:JC
M(<@J@2R%>=O>G8VZ 3#V8OE9;F50$+\)\+LY;7V26]<XWS]F]3GN/1TD<-/_
MYY4R#J?X?>Y\AMNP63L0U>**Z/:!LX:/B_;S6@*RT@#7'[<!4Z^%!&<J#JDZ
MUFUS-_V6(6W2M!VH?PJ:)(2-^7R^9/GM^-B4UHKDEI"MM\)K@FS@K1%$(CBO
M +LEK"EVV'@9Y:;=6ZZ<X1$-:$+9[*.\XA;4CTQ9UF6VM6JFV@2OBK!:,5.A
MAL3O5AX*??O%,HY:WEDJTZ1O.VQO!5'S0206Z0>!U2I'<7-_;W[A4*?0$L8&
MIOBA2!NL#ZDBX2W+0+D.9(4@K60-NFL39>"?Z005_:LX7A)A/P :G>,8@VJ#
M^F'8BT<<B0IM5X.1E7,Z'XX<U4Y)(ULX"X/[@^F$)E'C1<';O)87!.\9X/KC
M& N!=[6P+FJ*=;12'5)YM 7 N/UJ%_\:-&T'ZD3XZAM#[C;S*3>^!'^2U!*B
M^M:YYJ -G!HA)#)S9<BDK:ETT&@92=-N,1Z+7,R)F,EBOPF^2A[D:_C"9PV7
M_U9(M/I@I-X6/QAJ_VBD1A;WV4A1"+)*D)=">C3BT(;FV4AC+R@CL)8#QV*J
M;L)DZ^@:\J_);Q?^:D.\/@X!^PI-9.;7L"V3+W[$ MZ1 1WM)B[*.Z[EEOIR
MK7P7S;YB2N[Y'U!+ P04    "  %.&Y;&:C*8_$$  "]+P  %0   &IB:6\M
M,C R-3$Q,3-?<')E+GAM;-6:T7+B-A2&[W=FWT%U;]J9&F.3[#9,R XER0Y3
MDC# MIW>[ C[ &IEB9%$@+=?R: -!I/%R;9CY2* K?_X/^<3,I)U^6&54O0(
M0A+.6EY8JWL(6,P3PJ8M;R%]+&-"/"059@FFG$'+6X/T/ER]?7/Y@^^CZ]ON
M/?+13*FY; ;!<KFL)1/")*<+I4/*6LS3 /F^;=\9?4)_;"[71 .@@"6@Z#R,
MT&\+0I-F5(_.Z^^CJ!;NB@1@$PTE6$$3A6$0G@6F)3IKGD?->@/U[] -E@H$
M0R.2PJZ6S]>"3&<*_13_C#+1-6<,*(4UNB4,LYA@BH;6\"^HR^(::E.*!D8F
MM4L)XA&2VC8J)>S?IODW-M[1VS=(_^DR,ID=;7FF&-M:K,:"UKB8:K?U1F!%
MWJYF=2!:-C))>'%Q$61G\^TE*6JM+Q &?]WUAO$,4NQK!!I9O'<I[2917]6[
MYLZ#S4G;7I*FS"+U>)S5_H2TT-$6YI-OF_GFD!]&?B.LK63B79E+;JHJ.(4!
M3)!Y_33H?KTF!L$?-7NUROI3QCX,PT:@\(HSGJX#HPBN>;Q(@2G[VF;)#5-$
MK;MLPD6:Y>&AK*3-F8!)R_MG3+AOHQDW/PYTH,]E JGU7'\I)$GG%#P4[&0S
M%[KG,)6U[ND#.0&L%+ $$AO&)/"?Y'NU(;KMMCS.Y6^_MQDN"7%MRA^#!$AV
M1?,F*TY6&/WA<X?KH:(]EDK@6.4+0$T_X<(>I'@,M.45B(+O:6@(\4+HA&]6
M\0RS*=SC%$[U5:S-V]M%V!9Q+C(6L8VJW^;X'7X#MBV".18ZGA_/]&!GU1/!
MT\)2;:_&G_/+10*BY>D14P\ 'IH+PDTC?<1#"ZDM\;DQCZDY!Q,0 I+>I@A'
MS69.]6 J(6OYG9FU=5=-3'>]I7AZ*JP]474I[1FU>!K.X-F,(!V=@<"TJX>H
MU>^P/A73$7%U<1TQ;+&=.8/-W@-&NHRGTLIKJ@LI[].R>><<FSYHK_H6G5SK
M>WM92'OBZM/:,VRQO7<&VV9L&,"4F$29*O/CHEA;76C%?BVS7QUCIJ=P7,RY
MR$H[U!6&#E_H(7[=X4E)A-\(576BW[!O 5\X!OB64+A?I&,0Y6CNZJJ.;M?K
MEE.C[ABG$5YU$UT&,B&;98270#L:I.H$CQJW.$/'<+:31!=9;E]ZA$%8#F5A
M@*IC+#1M$;HS[SZ63/1:A)&+"*,GA*[-S0^3:;P68<-%A(TGA.[,TW/)=/3;
M!S'B2_8B@+MR1_#M6K;PSMV$E_V:?A!]P1^)>=+R$H(',1S!>.#;LG1G42:7
M3Y]+A>G?9%Y^@E@<P1&.>ZXM17?6:,QXTA: RW#+:ZI+*N_3LG%G+<8\.J;]
M&6<EI^J'NNHR.O1J.;FSI/*G]J> =7B:+MAVIBI/A75$7%UB1PQOL9VYL\(R
MY)3$1!$VO=,W8T&,M1.??!<HJPNLR*VEY<X"2E^ Z7*@?RUEC[+,Y@_Q,)F<
M/BP^%Z&Z])YS;2FZLX:RETU7R@6(U[,LB.,,T0+OEJL["RMV;TT8C4=$T=)[
MB)YTU>5VZ-5R<F?U9"2PV9HZ7*=C?O+M;D]474)[1BT>U]9';E(04YW'1\&7
M:J;'BCEF)7<0'0E1773/VK8@75L<N5GI'LDD,>8VNSE*4BS05QYA@6?+[W]8
M%KD,#NK2TP?,OO/-&?//[*+61[X 4$L! A0#%     @ !3AN6V9P/2PC$P
M)WL   T              ( !     &0R-C<V-F0X:RYH=&U02P$"% ,4
M"  %.&Y;T)YCPXD"  !Y!@  $               @ %.$P  9#(V-S8V9&5X
M,C,Q+FAT;5!+ 0(4 Q0    (  4X;EM-/LME'A\  !8D 0 0
M  "  046  !D,C8W-C9D97@Y.3$N:'1M4$L! A0#%     @ !3AN6ZM#(@D=
MD0  A(4$ !               ( !434  &0R-C<V-F1E>#DY,BYH=&U02P$"
M% ,4    "  %.&Y;^O&+MT #  !%"P  $0              @ &<Q@  :F)I
M;RTR,#(U,3$Q,RYX<V102P$"% ,4    "  %.&Y;G."G1\T&  "B3   %0
M            @ $+R@  :F)I;RTR,#(U,3$Q,U]L86(N>&UL4$L! A0#%
M  @ !3AN6QFHRF/Q!   O2\  !4              ( !"]$  &IB:6\M,C R
C-3$Q,3-?<')E+GAM;%!+!08     !P ' +H!   OU@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d26766d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="jbio-20251113.xsd" xlink:type="simple"/>
    <context id="duration_2025-11-13_to_2025-11-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001798749</identifier>
        </entity>
        <period>
            <startDate>2025-11-13</startDate>
            <endDate>2025-11-13</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2025-11-13_to_2025-11-13"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-319">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-11-13_to_2025-11-13"
      id="Hidden_dei_EntityCentralIndexKey">0001798749</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-330">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-331">2025-11-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-332">Jade Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-333">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-334">001-40544</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-335">83-1377888</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-336">221 Crescent St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-337">Building 23</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-338">Suite 105</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-339">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-340">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-341">02453</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-342">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-343">312-3013</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-344">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-345">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-346">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-347">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-348">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-349">JBIO</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-350">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-11-13_to_2025-11-13" id="ixv-351">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
